These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
75-3108137
|
State of Incorporation
|
|
IRS Employer Identification No.
|
|
|
|
11825 N. Pennsylvania Street
|
|
|
Carmel, Indiana 46032
|
|
(317) 817-6100
|
Address of principal executive offices
|
|
Telephone
|
PART I - FINANCIAL INFORMATION
|
Page
|
|
|
|
|
Item 1.
|
Financial Statements
|
|
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
Item 2.
|
||
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
PART II - OTHER INFORMATION
|
|
|
|
|
|
Item 1.
|
||
|
|
|
Item 1A.
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 5.
|
||
|
|
|
Item 6.
|
ITEM 1.
|
FINANCIAL STATEMENTS.
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
|
(unaudited)
|
|
|
||||
Investments:
|
|
|
|
||||
Fixed maturities, available for sale, at fair value (amortized cost: March 31, 2012 - $22,021.2; December 31, 2011 - $21,779.1)
|
$
|
23,777.7
|
|
|
$
|
23,516.0
|
|
Equity securities at fair value (cost: March 31, 2012 - $172.7; December 31, 2011 - $177.0)
|
176.5
|
|
|
175.1
|
|
||
Mortgage loans
|
1,546.7
|
|
|
1,602.8
|
|
||
Policy loans
|
277.8
|
|
|
279.7
|
|
||
Trading securities
|
122.3
|
|
|
91.6
|
|
||
Investments held by variable interest entities
|
564.7
|
|
|
496.3
|
|
||
Other invested assets
|
270.9
|
|
|
202.8
|
|
||
Total investments
|
26,736.6
|
|
|
26,364.3
|
|
||
Cash and cash equivalents - unrestricted
|
173.5
|
|
|
436.0
|
|
||
Cash and cash equivalents held by variable interest entities
|
65.8
|
|
|
74.4
|
|
||
Accrued investment income
|
313.6
|
|
|
288.7
|
|
||
Present value of future profits
|
675.4
|
|
|
697.7
|
|
||
Deferred acquisition costs
|
790.4
|
|
|
797.1
|
|
||
Reinsurance receivables
|
3,052.7
|
|
|
3,091.1
|
|
||
Income tax assets, net
|
819.9
|
|
|
865.4
|
|
||
Assets held in separate accounts
|
16.0
|
|
|
15.0
|
|
||
Other assets
|
402.3
|
|
|
292.2
|
|
||
Total assets
|
$
|
33,046.2
|
|
|
$
|
32,921.9
|
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
|
(unaudited)
|
|
|
||||
Liabilities:
|
|
|
|
||||
Liabilities for insurance products:
|
|
|
|
||||
Interest-sensitive products
|
$
|
13,103.4
|
|
|
$
|
13,165.5
|
|
Traditional products
|
10,517.9
|
|
|
10,482.7
|
|
||
Claims payable and other policyholder funds
|
1,000.8
|
|
|
1,034.3
|
|
||
Liabilities related to separate accounts
|
16.0
|
|
|
15.0
|
|
||
Other liabilities
|
721.0
|
|
|
556.3
|
|
||
Investment borrowings
|
1,684.9
|
|
|
1,676.5
|
|
||
Borrowings related to variable interest entities
|
519.9
|
|
|
519.9
|
|
||
Notes payable – direct corporate obligations
|
799.3
|
|
|
857.9
|
|
||
Total liabilities
|
28,363.2
|
|
|
28,308.1
|
|
||
Commitments and Contingencies
|
|
|
|
|
|
||
Shareholders' equity:
|
|
|
|
|
|
||
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: March 31, 2012 - 239,219,445; December 31, 2011 – 241,304,503)
|
2.4
|
|
|
2.4
|
|
||
Additional paid-in capital
|
4,345.6
|
|
|
4,361.9
|
|
||
Accumulated other comprehensive income
|
808.0
|
|
|
781.6
|
|
||
Accumulated deficit
|
(473.0
|
)
|
|
(532.1
|
)
|
||
Total shareholders' equity
|
4,683.0
|
|
|
4,613.8
|
|
||
Total liabilities and shareholders' equity
|
$
|
33,046.2
|
|
|
$
|
32,921.9
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
686.3
|
|
|
$
|
667.2
|
|
Net investment income (loss):
|
|
|
|
|
|
||
General account assets
|
345.2
|
|
|
336.1
|
|
||
Policyholder and reinsurer accounts and other special-purpose portfolios
|
65.6
|
|
|
37.4
|
|
||
Realized investment gains (losses):
|
|
|
|
|
|
||
Net realized investment gains, excluding impairment losses
|
30.8
|
|
|
18.4
|
|
||
Other-than-temporary impairment losses:
|
|
|
|
|
|
||
Total other-than-temporary impairment losses
|
(7.9
|
)
|
|
(13.3
|
)
|
||
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income
|
—
|
|
|
—
|
|
||
Net impairment losses recognized
|
(7.9
|
)
|
|
(13.3
|
)
|
||
Total realized gains (losses)
|
22.9
|
|
|
5.1
|
|
||
Fee revenue and other income
|
3.9
|
|
|
3.4
|
|
||
Total revenues
|
1,123.9
|
|
|
1,049.2
|
|
||
Benefits and expenses:
|
|
|
|
|
|
||
Insurance policy benefits
|
689.0
|
|
|
683.2
|
|
||
Interest expense
|
28.8
|
|
|
29.2
|
|
||
Amortization
|
86.6
|
|
|
94.9
|
|
||
Loss on extinguishment of debt
|
.2
|
|
|
1.4
|
|
||
Other operating costs and expenses
|
227.0
|
|
|
170.1
|
|
||
Total benefits and expenses
|
1,031.6
|
|
|
978.8
|
|
||
Income before income taxes
|
92.3
|
|
|
70.4
|
|
||
Income tax expense on period income
|
33.2
|
|
|
25.0
|
|
||
Net income
|
$
|
59.1
|
|
|
$
|
45.4
|
|
Earnings per common share:
|
|
|
|
|
|
||
Basic:
|
|
|
|
|
|
||
Weighted average shares outstanding
|
240,895,000
|
|
|
251,121,000
|
|
||
Net income
|
$
|
.25
|
|
|
$
|
.18
|
|
Diluted:
|
|
|
|
|
|
||
Weighted average shares outstanding
|
297,343,000
|
|
|
307,498,000
|
|
||
Net income
|
$
|
.21
|
|
|
$
|
.16
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Net income
|
$
|
59.1
|
|
|
$
|
45.4
|
|
Other comprehensive income, before tax:
|
|
|
|
||||
Unrealized gains for the period
|
51.9
|
|
|
48.5
|
|
||
Amortization of present value of future profits and deferred acquisition costs for:
|
|
|
|
||||
Unrealized gains during the period
|
(20.0
|
)
|
|
(7.5
|
)
|
||
Amount related to premium deficiencies assuming the net unrealized gains had been realized
|
30.3
|
|
|
—
|
|
||
Reclassification adjustments:
|
|
|
|
||||
For net realized investment gains included in net income
|
(21.6
|
)
|
|
(8.8
|
)
|
||
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains included in net income
|
1.1
|
|
|
.4
|
|
||
Unrealized gains on investments
|
41.7
|
|
|
32.6
|
|
||
Change related to deferred compensation plan
|
.8
|
|
|
.3
|
|
||
Other comprehensive income before tax
|
42.5
|
|
|
32.9
|
|
||
Income tax expense related to items of accumulated other comprehensive income
|
(16.1
|
)
|
|
(12.3
|
)
|
||
Other comprehensive income, net of tax
|
26.4
|
|
|
20.6
|
|
||
Comprehensive income
|
$
|
85.5
|
|
|
$
|
66.0
|
|
|
Common stock and
additional
paid-in capital
|
|
Accumulated other
comprehensive income
(loss)
|
|
Retained earnings
(accumulated deficit)
|
|
Total
|
||||||||
Balance, December 31, 2010 (as originally reported)
|
$
|
4,426.7
|
|
|
$
|
238.3
|
|
|
$
|
(339.7
|
)
|
|
$
|
4,325.3
|
|
Cumulative effect of accounting change (adoption of ASU 2010-26)
|
—
|
|
|
14.4
|
|
|
(528.1
|
)
|
|
(513.7
|
)
|
||||
Balance, December 31, 2010 (as adjusted)
|
4,426.7
|
|
|
252.7
|
|
|
(867.8
|
)
|
|
3,811.6
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
45.4
|
|
|
45.4
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $10.8)
|
—
|
|
|
17.9
|
|
|
—
|
|
|
17.9
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $1.5)
|
—
|
|
|
2.7
|
|
|
—
|
|
|
2.7
|
|
||||
Stock option and restricted stock plans
|
1.9
|
|
|
—
|
|
|
—
|
|
|
1.9
|
|
||||
Balance, March 31, 2011
|
$
|
4,428.6
|
|
|
$
|
273.3
|
|
|
$
|
(822.4
|
)
|
|
$
|
3,879.5
|
|
|
|
|
|
|
|
|
|
||||||||
Balance, December 31, 2011 (as originally reported)
|
$
|
4,364.3
|
|
|
$
|
625.5
|
|
|
$
|
42.8
|
|
|
$
|
5,032.6
|
|
Cumulative effect of accounting change (adoption of ASU 2010-26)
|
—
|
|
|
156.1
|
|
|
(574.9
|
)
|
|
(418.8
|
)
|
||||
Balance, December 31, 2011 (as adjusted)
|
4,364.3
|
|
|
781.6
|
|
|
(532.1
|
)
|
|
4,613.8
|
|
||||
Net income
|
—
|
|
|
—
|
|
|
59.1
|
|
|
59.1
|
|
||||
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $14.3)
|
—
|
|
|
23.1
|
|
|
—
|
|
|
23.1
|
|
||||
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $1.8)
|
—
|
|
|
3.3
|
|
|
—
|
|
|
3.3
|
|
||||
Cost of shares acquired
|
(18.9
|
)
|
|
—
|
|
|
—
|
|
|
(18.9
|
)
|
||||
Stock option and restricted stock plans
|
2.6
|
|
|
—
|
|
|
—
|
|
|
2.6
|
|
||||
Balance, March 31, 2012
|
$
|
4,348.0
|
|
|
$
|
808.0
|
|
|
$
|
(473.0
|
)
|
|
$
|
4,683.0
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Insurance policy income
|
$
|
602.5
|
|
|
$
|
591.6
|
|
Net investment income
|
306.7
|
|
|
325.2
|
|
||
Fee revenue and other income
|
3.9
|
|
|
3.4
|
|
||
Insurance policy benefits
|
(565.3
|
)
|
|
(513.9
|
)
|
||
Interest expense
|
(26.5
|
)
|
|
(16.2
|
)
|
||
Deferrable policy acquisition costs
|
(46.2
|
)
|
|
(53.2
|
)
|
||
Other operating costs
|
(193.2
|
)
|
|
(180.9
|
)
|
||
Taxes
|
(3.7
|
)
|
|
(.7
|
)
|
||
Net cash provided by operating activities
|
78.2
|
|
|
155.3
|
|
||
Cash flows from investing activities:
|
|
|
|
|
|
||
Sales of investments
|
670.3
|
|
|
1,248.1
|
|
||
Maturities and redemptions of investments
|
417.1
|
|
|
252.9
|
|
||
Purchases of investments
|
(1,305.2
|
)
|
|
(1,661.1
|
)
|
||
Net sales (purchases) of trading securities
|
7.9
|
|
|
(23.6
|
)
|
||
Change in cash and cash equivalents held by variable interest entities
|
8.6
|
|
|
(.3
|
)
|
||
Other
|
(9.8
|
)
|
|
(5.3
|
)
|
||
Net cash used by investing activities
|
(211.1
|
)
|
|
(189.3
|
)
|
||
Cash flows from financing activities:
|
|
|
|
|
|
||
Payments on notes payable
|
(59.4
|
)
|
|
(50.0
|
)
|
||
Issuance of common stock
|
.1
|
|
|
—
|
|
||
Payments to repurchase common stock
|
(18.9
|
)
|
|
—
|
|
||
Amounts received for deposit products
|
346.6
|
|
|
395.3
|
|
||
Withdrawals from deposit products
|
(406.3
|
)
|
|
(425.8
|
)
|
||
Issuance of investment borrowings:
|
|
|
|
||||
Federal Home Loan Bank
|
—
|
|
|
67.0
|
|
||
Payments on investment borrowings:
|
|
|
|
||||
Federal Home Loan Bank
|
—
|
|
|
(67.0
|
)
|
||
Related to variable interest entities and other
|
(.3
|
)
|
|
(32.8
|
)
|
||
Investment borrowings - repurchase agreements, net
|
8.6
|
|
|
—
|
|
||
Net cash used by financing activities
|
(129.6
|
)
|
|
(113.3
|
)
|
||
Net decrease in cash and cash equivalents
|
(262.5
|
)
|
|
(147.3
|
)
|
||
Cash and cash equivalents, beginning of period
|
436.0
|
|
|
571.9
|
|
||
Cash and cash equivalents, end of period
|
$
|
173.5
|
|
|
$
|
424.6
|
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized
|
$
|
1.6
|
|
|
$
|
(4.4
|
)
|
Net unrealized gains (losses) on all other investments
|
1,757.5
|
|
|
1,733.2
|
|
||
Adjustment to present value of future profits (a)
|
(207.3
|
)
|
|
(214.8
|
)
|
||
Adjustment to deferred acquisition costs
|
(285.4
|
)
|
|
(289.3
|
)
|
||
Unrecognized net loss related to deferred compensation plan
|
(7.5
|
)
|
|
(8.3
|
)
|
||
Deferred income tax liabilities
|
(450.9
|
)
|
|
(434.8
|
)
|
||
Accumulated other comprehensive income
|
$
|
808.0
|
|
|
$
|
781.6
|
|
(a)
|
The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 (the date our Predecessor emerged from bankruptcy).
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair value
|
|
Other-than-
temporary
impairments
included in
accumulated other
comprehensive
income
|
||||||||||
Corporate securities
|
$
|
14,574.1
|
|
|
$
|
1,425.3
|
|
|
$
|
(77.1
|
)
|
|
$
|
15,922.3
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
286.7
|
|
|
5.5
|
|
|
(3.1
|
)
|
|
289.1
|
|
|
—
|
|
|||||
States and political subdivisions
|
1,788.2
|
|
|
203.9
|
|
|
(8.2
|
)
|
|
1,983.9
|
|
|
—
|
|
|||||
Debt securities issued by foreign governments
|
.8
|
|
|
—
|
|
|
—
|
|
|
.8
|
|
|
—
|
|
|||||
Asset-backed securities
|
1,383.0
|
|
|
48.9
|
|
|
(24.9
|
)
|
|
1,407.0
|
|
|
—
|
|
|||||
Collateralized debt obligations
|
333.1
|
|
|
2.2
|
|
|
(2.9
|
)
|
|
332.4
|
|
|
—
|
|
|||||
Commercial mortgage-backed securities
|
1,399.7
|
|
|
103.5
|
|
|
(3.9
|
)
|
|
1,499.3
|
|
|
—
|
|
|||||
Mortgage pass-through securities
|
28.5
|
|
|
1.6
|
|
|
—
|
|
|
30.1
|
|
|
—
|
|
|||||
Collateralized mortgage obligations
|
2,227.1
|
|
|
94.2
|
|
|
(8.5
|
)
|
|
2,312.8
|
|
|
(10.8
|
)
|
|||||
Total fixed maturities, available for sale
|
$
|
22,021.2
|
|
|
$
|
1,885.1
|
|
|
$
|
(128.6
|
)
|
|
$
|
23,777.7
|
|
|
$
|
(10.8
|
)
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
163.1
|
|
|
$
|
165.0
|
|
Due after one year through five years
|
1,443.3
|
|
|
1,542.1
|
|
||
Due after five years through ten years
|
4,534.1
|
|
|
4,901.1
|
|
||
Due after ten years
|
10,509.3
|
|
|
11,587.9
|
|
||
Subtotal
|
16,649.8
|
|
|
18,196.1
|
|
||
Structured securities
|
5,371.4
|
|
|
5,581.6
|
|
||
Total fixed maturities, available for sale
|
$
|
22,021.2
|
|
|
$
|
23,777.7
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Credit losses on fixed maturity securities, available for sale, beginning of period
|
$
|
(2.0
|
)
|
|
$
|
(6.1
|
)
|
Add: credit losses on other-than-temporary impairments not previously recognized
|
—
|
|
|
—
|
|
||
Less: credit losses on securities sold
|
.1
|
|
|
4.3
|
|
||
Less: credit losses on securities impaired due to intent to sell (a)
|
—
|
|
|
—
|
|
||
Add: credit losses on previously impaired securities
|
—
|
|
|
—
|
|
||
Less: increases in cash flows expected on previously impaired securities
|
—
|
|
|
—
|
|
||
Credit losses on fixed maturity securities, available for sale, end of period
|
$
|
(1.9
|
)
|
|
$
|
(1.8
|
)
|
(a)
|
Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
195.3
|
|
|
$
|
(3.1
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
195.3
|
|
|
$
|
(3.1
|
)
|
States and political subdivisions
|
|
4.1
|
|
|
(.3
|
)
|
|
126.4
|
|
|
(7.9
|
)
|
|
130.5
|
|
|
(8.2
|
)
|
||||||
Corporate securities
|
|
1,204.7
|
|
|
(38.9
|
)
|
|
388.5
|
|
|
(38.2
|
)
|
|
1,593.2
|
|
|
(77.1
|
)
|
||||||
Asset-backed securities
|
|
287.7
|
|
|
(6.7
|
)
|
|
211.8
|
|
|
(18.2
|
)
|
|
499.5
|
|
|
(24.9
|
)
|
||||||
Collateralized debt obligations
|
|
198.5
|
|
|
(2.7
|
)
|
|
11.0
|
|
|
(.2
|
)
|
|
209.5
|
|
|
(2.9
|
)
|
||||||
Commercial mortgage-backed securities
|
|
89.6
|
|
|
(2.0
|
)
|
|
29.2
|
|
|
(1.9
|
)
|
|
118.8
|
|
|
(3.9
|
)
|
||||||
Mortgage pass-through securities
|
|
.5
|
|
|
—
|
|
|
2.2
|
|
|
—
|
|
|
2.7
|
|
|
—
|
|
||||||
Collateralized mortgage obligations
|
|
331.9
|
|
|
(6.0
|
)
|
|
63.7
|
|
|
(2.5
|
)
|
|
395.6
|
|
|
(8.5
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
2,312.3
|
|
|
$
|
(59.7
|
)
|
|
$
|
832.8
|
|
|
$
|
(68.9
|
)
|
|
$
|
3,145.1
|
|
|
$
|
(128.6
|
)
|
Equity securities
|
|
$
|
3.5
|
|
|
$
|
(.3
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3.5
|
|
|
$
|
(.3
|
)
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
9.1
|
|
|
$
|
—
|
|
|
$
|
.2
|
|
|
$
|
—
|
|
|
$
|
9.3
|
|
|
$
|
—
|
|
States and political subdivisions
|
|
6.9
|
|
|
(.2
|
)
|
|
155.4
|
|
|
(13.4
|
)
|
|
162.3
|
|
|
(13.6
|
)
|
||||||
Debt securities issued by foreign governments
|
|
.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.5
|
|
|
—
|
|
||||||
Corporate securities
|
|
1,394.7
|
|
|
(57.0
|
)
|
|
466.2
|
|
|
(79.9
|
)
|
|
1,860.9
|
|
|
(136.9
|
)
|
||||||
Asset-backed securities
|
|
437.6
|
|
|
(14.5
|
)
|
|
147.5
|
|
|
(22.2
|
)
|
|
585.1
|
|
|
(36.7
|
)
|
||||||
Collateralized debt obligations
|
|
268.8
|
|
|
(6.3
|
)
|
|
1.7
|
|
|
—
|
|
|
270.5
|
|
|
(6.3
|
)
|
||||||
Commercial mortgage-backed securities
|
|
168.8
|
|
|
(5.2
|
)
|
|
33.0
|
|
|
(2.7
|
)
|
|
201.8
|
|
|
(7.9
|
)
|
||||||
Mortgage pass-through securities
|
|
1.2
|
|
|
—
|
|
|
2.2
|
|
|
(.1
|
)
|
|
3.4
|
|
|
(.1
|
)
|
||||||
Collateralized mortgage obligations
|
|
645.0
|
|
|
(20.8
|
)
|
|
29.7
|
|
|
(.6
|
)
|
|
674.7
|
|
|
(21.4
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
2,932.6
|
|
|
$
|
(104.0
|
)
|
|
$
|
835.9
|
|
|
$
|
(118.9
|
)
|
|
$
|
3,768.5
|
|
|
$
|
(222.9
|
)
|
Equity securities
|
|
$
|
41.6
|
|
|
$
|
(3.0
|
)
|
|
$
|
.4
|
|
|
$
|
—
|
|
|
$
|
42.0
|
|
|
$
|
(3.0
|
)
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Net income for basic earnings per share
|
$
|
59.1
|
|
|
$
|
45.4
|
|
Add: interest expense on 7.0% Convertible Senior Debentures due 2016 (the “7.0% Debentures”), net of income taxes
|
3.7
|
|
|
3.7
|
|
||
Net income for diluted earnings per share
|
$
|
62.8
|
|
|
$
|
49.1
|
|
Shares:
|
|
|
|
|
|
||
Weighted average shares outstanding for basic earnings per share
|
240,895
|
|
|
251,121
|
|
||
Effect of dilutive securities on weighted average shares:
|
|
|
|
|
|
||
7% Debentures
|
53,367
|
|
|
53,367
|
|
||
Stock option and restricted stock plans
|
2,582
|
|
|
2,748
|
|
||
Warrants
|
499
|
|
|
262
|
|
||
Dilutive potential common shares
|
56,448
|
|
|
56,377
|
|
||
Weighted average shares outstanding for diluted earnings per share
|
297,343
|
|
|
307,498
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Revenues:
|
|
|
|
||||
Bankers Life:
|
|
|
|
||||
Insurance policy income:
|
|
|
|
||||
Annuities
|
$
|
7.2
|
|
|
$
|
8.4
|
|
Health
|
334.1
|
|
|
339.8
|
|
||
Life
|
65.2
|
|
|
51.8
|
|
||
Net investment income (a)
|
234.9
|
|
|
209.6
|
|
||
Fee revenue and other income (a)
|
2.9
|
|
|
2.3
|
|
||
Total Bankers Life revenues
|
644.3
|
|
|
611.9
|
|
||
Washington National:
|
|
|
|
|
|
||
Insurance policy income:
|
|
|
|
|
|
||
Health
|
142.4
|
|
|
140.2
|
|
||
Life
|
4.3
|
|
|
4.1
|
|
||
Other
|
.7
|
|
|
1.1
|
|
||
Net investment income (a)
|
50.0
|
|
|
46.3
|
|
||
Fee revenue and other income (a)
|
.2
|
|
|
.3
|
|
||
Total Washington National revenues
|
197.6
|
|
|
192.0
|
|
||
Colonial Penn:
|
|
|
|
|
|
||
Insurance policy income:
|
|
|
|
|
|
||
Health
|
1.4
|
|
|
1.6
|
|
||
Life
|
52.0
|
|
|
48.7
|
|
||
Net investment income (a)
|
10.0
|
|
|
10.3
|
|
||
Fee revenue and other income (a)
|
.2
|
|
|
.2
|
|
||
Total Colonial Penn revenues
|
63.6
|
|
|
60.8
|
|
||
Other CNO Business:
|
|
|
|
|
|
||
Insurance policy income:
|
|
|
|
|
|
||
Annuities
|
2.5
|
|
|
2.3
|
|
||
Health
|
6.7
|
|
|
7.3
|
|
||
Life
|
69.6
|
|
|
61.3
|
|
||
Other
|
.2
|
|
|
.6
|
|
||
Net investment income (a)
|
92.7
|
|
|
94.7
|
|
||
Total Other CNO Business revenues
|
171.7
|
|
|
166.2
|
|
||
Corporate operations:
|
|
|
|
|
|
||
Net investment income
|
23.2
|
|
|
12.6
|
|
||
Fee and other income
|
.6
|
|
|
.6
|
|
||
Total corporate revenues
|
23.8
|
|
|
13.2
|
|
||
Total revenues
|
1,101.0
|
|
|
1,044.1
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Expenses:
|
|
|
|
||||
Bankers Life:
|
|
|
|
||||
Insurance policy benefits
|
$
|
420.9
|
|
|
$
|
404.8
|
|
Amortization
|
56.9
|
|
|
68.5
|
|
||
Interest expense on investment borrowings
|
1.4
|
|
|
1.2
|
|
||
Other operating costs and expenses
|
94.6
|
|
|
75.2
|
|
||
Total Bankers Life expenses
|
573.8
|
|
|
549.7
|
|
||
Washington National:
|
|
|
|
|
|
||
Insurance policy benefits
|
115.7
|
|
|
112.2
|
|
||
Amortization
|
12.7
|
|
|
13.4
|
|
||
Interest expense on investment borrowings
|
.7
|
|
|
—
|
|
||
Other operating costs and expenses
|
43.8
|
|
|
42.1
|
|
||
Total Washington National expenses
|
172.9
|
|
|
167.7
|
|
||
Colonial Penn:
|
|
|
|
|
|
||
Insurance policy benefits
|
42.1
|
|
|
38.7
|
|
||
Amortization
|
3.7
|
|
|
4.0
|
|
||
Other operating costs and expenses
|
27.6
|
|
|
23.8
|
|
||
Total Colonial Penn expenses
|
73.4
|
|
|
66.5
|
|
||
Other CNO Business:
|
|
|
|
|
|
||
Insurance policy benefits
|
121.9
|
|
|
127.5
|
|
||
Amortization
|
7.5
|
|
|
8.6
|
|
||
Interest expense on investment borrowings
|
5.1
|
|
|
4.9
|
|
||
Other operating costs and expenses
|
39.5
|
|
|
17.8
|
|
||
Total Other CNO Business expenses
|
174.0
|
|
|
158.8
|
|
||
Corporate operations:
|
|
|
|
|
|
||
Interest expense on corporate debt
|
17.5
|
|
|
20.6
|
|
||
Interest expense on borrowings of variable interest entities
|
4.0
|
|
|
2.5
|
|
||
Interest expense on investment borrowings
|
.1
|
|
|
—
|
|
||
Loss on extinguishment of debt
|
.2
|
|
|
1.4
|
|
||
Other operating costs and expenses
|
21.5
|
|
|
11.2
|
|
||
Total corporate expenses
|
43.3
|
|
|
35.7
|
|
||
Total expenses
|
1,037.4
|
|
|
978.4
|
|
||
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes:
|
|
|
|
|
|||
Bankers Life
|
70.5
|
|
|
62.2
|
|
||
Washington National
|
24.7
|
|
|
24.3
|
|
||
Colonial Penn
|
(9.8
|
)
|
|
(5.7
|
)
|
||
Other CNO Business
|
(2.3
|
)
|
|
7.4
|
|
||
Corporate operations
|
(19.5
|
)
|
|
(22.5
|
)
|
||
Income before net realized investment losses and fair value changes in embedded derivative liabilities (net of related amortization) and income taxes
|
$
|
63.6
|
|
|
$
|
65.7
|
|
(a)
|
It is not practicable to provide additional components of revenue by product or services.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Total segment revenues
|
$
|
1,101.0
|
|
|
$
|
1,044.1
|
|
Net realized investment gains
|
22.9
|
|
|
5.1
|
|
||
Consolidated revenues
|
$
|
1,123.9
|
|
|
$
|
1,049.2
|
|
|
|
|
|
||||
Total segment expenses
|
$
|
1,037.4
|
|
|
$
|
978.4
|
|
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
(11.6
|
)
|
|
—
|
|
||
Amortization related to fair value changes in embedded derivative liabilities
|
4.7
|
|
|
—
|
|
||
Amortization related to net realized investment gains
|
1.1
|
|
|
.4
|
|
||
Consolidated expenses
|
$
|
1,031.6
|
|
|
$
|
978.8
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Current tax expense
|
$
|
3.3
|
|
|
$
|
3.1
|
|
Deferred tax provision
|
29.9
|
|
|
21.9
|
|
||
Total income tax expense
|
$
|
33.2
|
|
|
$
|
25.0
|
|
|
Three months ended
|
||||
|
March 31,
|
||||
|
2012
|
|
2011
|
||
U.S. statutory corporate rate
|
35.0
|
%
|
|
35.0
|
%
|
Other nondeductible benefits
|
1.2
|
|
|
(1.0
|
)
|
State taxes
|
1.1
|
|
|
.7
|
|
Provision for tax issues, tax credits and other
|
(1.3
|
)
|
|
.8
|
|
Effective tax rate
|
36.0
|
%
|
|
35.5
|
%
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
Deferred tax assets:
|
|
|
|
||||
Net federal operating loss carryforwards attributable to:
|
|
|
|
||||
Life insurance subsidiaries
|
$
|
545.1
|
|
|
$
|
583.0
|
|
Non-life companies
|
863.6
|
|
|
862.2
|
|
||
Net state operating loss carryforwards
|
16.6
|
|
|
16.8
|
|
||
Tax credits
|
34.8
|
|
|
32.6
|
|
||
Capital loss carryforwards
|
331.1
|
|
|
342.3
|
|
||
Deductible temporary differences:
|
|
|
|
|
|
||
Insurance liabilities
|
764.8
|
|
|
744.4
|
|
||
Other
|
46.8
|
|
|
64.8
|
|
||
Gross deferred tax assets
|
2,602.8
|
|
|
2,646.1
|
|
||
Deferred tax liabilities:
|
|
|
|
|
|
||
Investments
|
(25.8
|
)
|
|
(24.2
|
)
|
||
Present value of future profits and deferred acquisition costs
|
(348.4
|
)
|
|
(363.7
|
)
|
||
Unrealized appreciation on investments
|
(450.9
|
)
|
|
(434.8
|
)
|
||
Gross deferred tax liabilities
|
(825.1
|
)
|
|
(822.7
|
)
|
||
Net deferred tax assets before valuation allowance
|
1,777.7
|
|
|
1,823.4
|
|
||
Valuation allowance
|
(938.4
|
)
|
|
(938.4
|
)
|
||
Net deferred tax assets
|
839.3
|
|
|
885.0
|
|
||
Current income taxes accrued
|
(19.4
|
)
|
|
(19.6
|
)
|
||
Income tax assets, net
|
$
|
819.9
|
|
|
$
|
865.4
|
|
Year of expiration
|
|
Net operating loss carryforwards (a)
|
|
Capital loss
|
|
Total loss
|
||||||||||||||||
|
|
Life
|
|
Non-life
|
|
carryforwards
|
|
carryforwards
|
||||||||||||||
2013
|
|
$
|
—
|
|
|
|
|
$
|
—
|
|
|
|
|
$
|
908.3
|
|
|
(b)
|
|
$
|
908.3
|
|
2014
|
|
—
|
|
|
|
|
—
|
|
|
|
|
28.7
|
|
|
|
|
28.7
|
|
||||
2015
|
|
—
|
|
|
|
|
—
|
|
|
|
|
8.9
|
|
|
|
|
8.9
|
|
||||
2018
|
|
1,323.8
|
|
|
(a)
|
|
—
|
|
|
|
|
—
|
|
|
|
|
1,323.8
|
|
||||
2021
|
|
29.6
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
29.6
|
|
||||
2022
|
|
204.1
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
204.1
|
|
||||
2023
|
|
—
|
|
|
(b)
|
|
1,975.2
|
|
|
(a)
|
|
—
|
|
|
|
|
1,975.2
|
|
||||
2024
|
|
—
|
|
|
|
|
3.2
|
|
|
|
|
—
|
|
|
|
|
3.2
|
|
||||
2025
|
|
—
|
|
|
|
|
118.8
|
|
|
|
|
—
|
|
|
|
|
118.8
|
|
||||
2027
|
|
—
|
|
|
|
|
216.8
|
|
|
|
|
—
|
|
|
|
|
216.8
|
|
||||
2028
|
|
—
|
|
|
|
|
.5
|
|
|
|
|
—
|
|
|
|
|
.5
|
|
||||
2029
|
|
—
|
|
|
|
|
148.8
|
|
|
|
|
—
|
|
|
|
|
148.8
|
|
||||
2031
|
|
—
|
|
|
|
|
4.0
|
|
|
|
|
—
|
|
|
|
|
4.0
|
|
||||
Total
|
|
$
|
1,557.5
|
|
|
|
|
$
|
2,467.3
|
|
|
|
|
$
|
945.9
|
|
|
|
|
$
|
4,970.7
|
|
(a)
|
The allocation of the NOLs summarized above assumes the IRS does not take an adverse position in the future regarding the tax position we plan to take in our tax returns with respect to the allocation of CODI. If the IRS disagrees with the tax position we plan to take with respect to the allocation of CODI, and their position prevails, approximately
$631 million
of the NOLs expiring in 2018 would be characterized as non-life NOLs.
|
(b)
|
Capital loss carryforwards expiring in 2013 include a
$742 million
loss on our investment in Senior Health which was worthless when it was transferred to the Independent Trust in 2008. Due to uncertainties in the Code, we have reflected this loss as an ordinary loss in our tax return. If classifying this loss as ordinary is ultimately determined to
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
7.0% Debentures
|
$
|
293.0
|
|
|
$
|
293.0
|
|
Senior Secured Credit Agreement (as defined below)
|
245.8
|
|
|
255.2
|
|
||
9.0% Senior Secured Notes due January 2018 (the “9.0% Senior Secured Notes”)
|
275.0
|
|
|
275.0
|
|
||
Senior Health Note due November 12, 2013 (the “Senior Health Note”)
|
—
|
|
|
50.0
|
|
||
Unamortized discount on 7.0% Debentures
|
(12.4
|
)
|
|
(12.9
|
)
|
||
Unamortized discount on Senior Secured Credit Agreement
|
(2.1
|
)
|
|
(2.4
|
)
|
||
Direct corporate obligations
|
$
|
799.3
|
|
|
$
|
857.9
|
|
(i)
|
a change in the definition of “Total Capitalization” (used to calculate compliance with the Debt to Total Capitalization Ratio covenant) to provide that any change to the Company's shareholders' equity resulting from the adoption by the Company of ASU 2010-26, related to the accounting for deferred acquisition costs, shall be disregarded for the purpose of such covenant to the extent the Company going forward quantifies the impact of ASU 2010-26 for each fiscal quarter or fiscal year and the cumulative impact since its adoption; and
|
(ii)
|
an increase in the cap on investments in “Capital Stock” (as defined in the amended credit agreement) from
1 percent
to
3 percent
.
|
Year ending March 31,
|
|
||
2013
|
$
|
33.8
|
|
2014
|
60.0
|
|
|
2015
|
77.5
|
|
|
2016
|
74.5
|
|
|
2017
|
293.0
|
|
|
Thereafter
|
275.0
|
|
|
|
$
|
813.8
|
|
•
|
incur or guarantee additional indebtedness or issue preferred stock;
|
•
|
pay dividends or make other distributions to shareholders;
|
•
|
purchase or redeem capital stock or subordinated indebtedness;
|
•
|
make certain investments;
|
•
|
create liens;
|
•
|
incur restrictions on the Company's ability and the ability of the Restricted Subsidiaries to pay dividends or make
|
•
|
other payments to the Company;
|
•
|
sell assets, including capital stock of the Company's subsidiaries;
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company's assets; and
|
•
|
engage in transactions with affiliates.
|
Amount
|
|
Maturity
|
|
Interest rate at
|
||
borrowed
|
|
date
|
|
March 31, 2012
|
||
$
|
100.0
|
|
|
October 2013
|
|
Variable rate – 0.572%
|
100.0
|
|
|
November 2013
|
|
Variable rate – 0.583%
|
|
67.0
|
|
|
February 2014
|
|
Fixed rate – 1.830%
|
|
50.0
|
|
|
August 2014
|
|
Variable rate – 0.633%
|
|
100.0
|
|
|
September 2015
|
|
Variable rate – 0.853%
|
|
150.0
|
|
|
October 2015
|
|
Variable rate – 0.592%
|
|
100.0
|
|
|
November 2015
|
|
Fixed rate – 4.890%
|
|
146.0
|
|
|
November 2015
|
|
Fixed rate – 5.300%
|
|
100.0
|
|
|
December 2015
|
|
Fixed rate – 4.710%
|
|
100.0
|
|
|
June 2016
|
|
Variable rate – 0.682%
|
|
75.0
|
|
|
June 2016
|
|
Variable rate – 0.630%
|
|
75.0
|
|
|
August 2016
|
|
Variable rate – 0.701%
|
|
100.0
|
|
|
October 2016
|
|
Variable rate – 0.761%
|
|
50.0
|
|
|
November 2016
|
|
Variable rate – 0.750%
|
|
50.0
|
|
|
November 2016
|
|
Variable rate – 0.712%
|
|
100.0
|
|
|
June 2017
|
|
Variable rate – 0.763%
|
|
50.0
|
|
|
August 2017
|
|
Variable rate – 0.703%
|
|
100.0
|
|
|
October 2017
|
|
Variable rate – 1.002%
|
|
37.0
|
|
|
November 2017
|
|
Fixed rate – 3.750%
|
|
$
|
1,650.0
|
|
|
|
|
|
Balance, December 31, 2011
|
241,305
|
|
|
|
Treasury stock purchased and retired
|
(2,437
|
)
|
|
|
Stock options exercised
|
30
|
|
|
|
Restricted stock vested
|
321
|
|
|
(a)
|
Balance, March 31, 2012
|
239,219
|
|
|
|
(a)
|
Such amount was reduced by
142 thousand
shares which were tendered to the Company for the payment of federal and state taxes owed on the vesting of restricted stock.
|
|
March 31, 2012
|
||||||||||
|
Amounts prior to adoption of ASU 2010-26
|
|
Effect of adoption of ASU 2010-26
|
|
As reported
|
||||||
Deferred acquisition costs
|
$
|
1,580.4
|
|
|
$
|
(790.0
|
)
|
|
$
|
790.4
|
|
Income tax assets, net
|
525.0
|
|
|
294.9
|
|
|
819.9
|
|
|||
Other assets
|
426.2
|
|
|
(23.9
|
)
|
|
402.3
|
|
|||
Total assets
|
33,565.2
|
|
|
(519.0
|
)
|
|
33,046.2
|
|
|||
|
|
|
|
|
|
||||||
Other liabilities
|
713.2
|
|
|
7.8
|
|
|
721.0
|
|
|||
Total liabilities
|
28,355.4
|
|
|
7.8
|
|
|
28,363.2
|
|
|||
|
|
|
|
|
|
||||||
Accumulated other comprehensive income
|
749.5
|
|
|
58.5
|
|
|
808.0
|
|
|||
Retained earnings (accumulated deficit)
|
112.3
|
|
|
(585.3
|
)
|
|
(473.0
|
)
|
|||
Total shareholders' equity
|
5,209.8
|
|
|
(526.8
|
)
|
|
4,683.0
|
|
|||
Total liabilities and shareholders' equity
|
33,565.2
|
|
|
(519.0
|
)
|
|
33,046.2
|
|
|
Three months ended
|
||||||||||
|
March 31, 2012
|
||||||||||
|
Amounts prior to adoption of ASU 2010-26
|
|
Effect of adoption of ASU 2010-26
|
|
As reported
|
||||||
Amortization
|
$
|
131.8
|
|
|
$
|
(45.2
|
)
|
|
$
|
86.6
|
|
Other operating costs and expenses
|
165.5
|
|
|
61.5
|
|
|
227.0
|
|
|||
Total benefits and expenses
|
1,015.3
|
|
|
16.3
|
|
|
1,031.6
|
|
|||
Income before income taxes
|
108.6
|
|
|
(16.3
|
)
|
|
92.3
|
|
|||
Tax expense on period income
|
39.1
|
|
|
(5.9
|
)
|
|
33.2
|
|
|||
Net income
|
69.5
|
|
|
(10.4
|
)
|
|
59.1
|
|
|||
|
|
|
|
|
|
||||||
Earnings per common share:
|
|
|
|
|
|
||||||
Basic:
|
|
|
|
|
|
||||||
Net income
|
$
|
.29
|
|
|
$
|
(.04
|
)
|
|
$
|
.25
|
|
Diluted:
|
|
|
|
|
|
||||||
Net income
|
.25
|
|
|
(.04
|
)
|
|
.21
|
|
|
December 31, 2011
|
||||||||||
|
As originally reported
|
|
Effect of adoption of ASU 2010-26
|
|
As adjusted
|
||||||
Deferred acquisition costs
|
$
|
1,418.1
|
|
|
$
|
(621.0
|
)
|
|
$
|
797.1
|
|
Income tax assets, net
|
630.5
|
|
|
234.9
|
|
|
865.4
|
|
|||
Other assets
|
316.9
|
|
|
(24.7
|
)
|
|
292.2
|
|
|||
Total assets
|
33,332.7
|
|
|
(410.8
|
)
|
|
32,921.9
|
|
|||
|
|
|
|
|
|
||||||
Other liabilities
|
548.3
|
|
|
8.0
|
|
|
556.3
|
|
|||
Total liabilities
|
28,300.1
|
|
|
8.0
|
|
|
28,308.1
|
|
|||
|
|
|
|
|
|
||||||
Accumulated other comprehensive income
|
625.5
|
|
|
156.1
|
|
|
781.6
|
|
|||
Retained earnings (accumulated deficit)
|
42.8
|
|
|
(574.9
|
)
|
|
(532.1
|
)
|
|||
Total shareholders' equity
|
5,032.6
|
|
|
(418.8
|
)
|
|
4,613.8
|
|
|||
Total liabilities and shareholders' equity
|
33,332.7
|
|
|
(410.8
|
)
|
|
32,921.9
|
|
|
Three months ended
|
||||||||||
|
March 31, 2011
|
||||||||||
|
As originally reported
|
|
Effect of adoption of ASU 2010-26
|
|
As adjusted
|
||||||
Amortization
|
$
|
136.7
|
|
|
$
|
(41.8
|
)
|
|
$
|
94.9
|
|
Other operating costs and expenses
|
115.1
|
|
|
55.0
|
|
|
170.1
|
|
|||
Total benefits and expenses
|
965.6
|
|
|
13.2
|
|
|
978.8
|
|
|||
Income before income taxes
|
83.6
|
|
|
(13.2
|
)
|
|
70.4
|
|
|||
Tax expense on period income
|
29.7
|
|
|
(4.7
|
)
|
|
25.0
|
|
|||
Net income
|
53.9
|
|
|
(8.5
|
)
|
|
45.4
|
|
|||
|
|
|
|
|
|
||||||
Earnings per common share:
|
|
|
|
|
|
||||||
Basic:
|
|
|
|
|
|
||||||
Net income
|
$
|
.21
|
|
|
$
|
(.03
|
)
|
|
$
|
.18
|
|
Diluted:
|
|
|
|
|
|
||||||
Net income
|
.19
|
|
|
(.03
|
)
|
|
.16
|
|
|
Three months ended
|
||||||||||
|
March 31, 2011
|
||||||||||
|
As originally reported
|
|
Effect of adoption of ASU 2010-26
|
|
As adjusted
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
||||||
Deferrable policy acquisition costs
|
$
|
(109.4
|
)
|
|
$
|
56.2
|
|
|
$
|
(53.2
|
)
|
Other operating costs
|
(124.7
|
)
|
|
(56.2
|
)
|
|
(180.9
|
)
|
|||
Net cash used by operating activities
|
155.3
|
|
|
—
|
|
|
155.3
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Balance, beginning of period
|
$
|
797.1
|
|
|
$
|
999.6
|
|
Additions
|
46.2
|
|
|
53.2
|
|
||
Amortization
|
(56.8
|
)
|
|
(56.8
|
)
|
||
Amounts related to fair value adjustment of fixed maturities, available for sale
|
3.9
|
|
|
(6.7
|
)
|
||
Balance, end of period
|
$
|
790.4
|
|
|
$
|
989.3
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net income
|
$
|
59.1
|
|
|
$
|
45.4
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|||
Amortization and depreciation
|
91.1
|
|
|
101.5
|
|
||
Income taxes
|
29.5
|
|
|
24.3
|
|
||
Insurance liabilities
|
39.9
|
|
|
109.1
|
|
||
Accrual and amortization of investment income
|
(104.1
|
)
|
|
(48.3
|
)
|
||
Deferral of policy acquisition costs
|
(46.2
|
)
|
|
(53.2
|
)
|
||
Net realized investment gains
|
(22.9
|
)
|
|
(5.1
|
)
|
||
Loss on extinguishment of debt
|
.2
|
|
|
1.4
|
|
||
Other
|
31.6
|
|
|
(19.8
|
)
|
||
Net cash provided by operating activities
|
$
|
78.2
|
|
|
$
|
155.3
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Stock option and restricted stock plans
|
$
|
2.5
|
|
|
$
|
1.9
|
|
|
March 31, 2012
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
564.7
|
|
|
$
|
—
|
|
|
$
|
564.7
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(75.4
|
)
|
|
(75.4
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
65.8
|
|
|
—
|
|
|
65.8
|
|
|||
Accrued investment income
|
2.2
|
|
|
—
|
|
|
2.2
|
|
|||
Income tax assets, net
|
4.9
|
|
|
(1.5
|
)
|
|
3.4
|
|
|||
Other assets
|
16.2
|
|
|
—
|
|
|
16.2
|
|
|||
Total assets
|
$
|
653.8
|
|
|
$
|
(76.9
|
)
|
|
$
|
576.9
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
63.6
|
|
|
$
|
(.4
|
)
|
|
$
|
63.2
|
|
Borrowings related to variable interest entities
|
519.9
|
|
|
—
|
|
|
519.9
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
79.5
|
|
|
(79.5
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
663.0
|
|
|
$
|
(79.9
|
)
|
|
$
|
583.1
|
|
|
December 31, 2011
|
||||||||||
|
VIEs
|
|
Eliminations
|
|
Net effect on
consolidated
balance sheet
|
||||||
Assets:
|
|
|
|
|
|
||||||
Investments held by variable interest entities
|
$
|
496.3
|
|
|
$
|
—
|
|
|
$
|
496.3
|
|
Notes receivable of VIEs held by insurance subsidiaries
|
—
|
|
|
(45.3
|
)
|
|
(45.3
|
)
|
|||
Cash and cash equivalents held by variable interest entities
|
74.4
|
|
|
—
|
|
|
74.4
|
|
|||
Accrued investment income
|
1.7
|
|
|
—
|
|
|
1.7
|
|
|||
Income tax assets, net
|
6.8
|
|
|
(1.4
|
)
|
|
5.4
|
|
|||
Other assets
|
7.7
|
|
|
—
|
|
|
7.7
|
|
|||
Total assets
|
$
|
586.9
|
|
|
$
|
(46.7
|
)
|
|
$
|
540.2
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|||
Other liabilities
|
$
|
30.3
|
|
|
$
|
(.1
|
)
|
|
$
|
30.2
|
|
Borrowings related to variable interest entities
|
519.9
|
|
|
—
|
|
|
519.9
|
|
|||
Notes payable of VIEs held by insurance subsidiaries
|
49.3
|
|
|
(49.3
|
)
|
|
—
|
|
|||
Total liabilities
|
$
|
599.5
|
|
|
$
|
(49.4
|
)
|
|
$
|
550.1
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
.5
|
|
|
$
|
.5
|
|
Due after one year through five years
|
308.5
|
|
|
306.5
|
|
||
Due after five years through ten years
|
257.1
|
|
|
257.7
|
|
||
Total
|
$
|
566.1
|
|
|
$
|
564.7
|
|
•
|
Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities. Our Level 1 assets primarily include cash and exchange traded securities.
|
•
|
Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data. Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies. These models are primarily industry-standard models that consider various inputs such as interest rate, credit spread, reported trades, broker/dealer quotes, issuer spreads and other inputs that are observable or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. Financial assets in this category primarily include: certain public and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund and hedge fund investments; and most short-term investments; and non-exchange-traded derivatives such as call options to hedge liabilities related to our fixed index annuity products. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.
|
•
|
Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions. Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on non-binding broker prices or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information. Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities. Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.
|
|
Quoted prices in active markets
for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
15,654.3
|
|
|
$
|
268.0
|
|
|
$
|
15,922.3
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
20.0
|
|
|
267.5
|
|
|
1.6
|
|
|
289.1
|
|
||||
States and political subdivisions
|
—
|
|
|
1,974.3
|
|
|
9.6
|
|
|
1,983.9
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
.8
|
|
|
—
|
|
|
.8
|
|
||||
Asset-backed securities
|
—
|
|
|
1,384.3
|
|
|
22.7
|
|
|
1,407.0
|
|
||||
Collateralized debt obligations
|
—
|
|
|
—
|
|
|
332.4
|
|
|
332.4
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,499.3
|
|
|
—
|
|
|
1,499.3
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
27.9
|
|
|
2.2
|
|
|
30.1
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
2,298.1
|
|
|
14.7
|
|
|
2,312.8
|
|
||||
Total fixed maturities, available for sale
|
20.0
|
|
|
23,106.5
|
|
|
651.2
|
|
|
23,777.7
|
|
||||
Equity securities:
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
20.1
|
|
|
88.0
|
|
|
3.2
|
|
|
111.3
|
|
||||
Venture capital investments
|
—
|
|
|
—
|
|
|
65.2
|
|
|
65.2
|
|
||||
Total equity securities
|
20.1
|
|
|
88.0
|
|
|
68.4
|
|
|
176.5
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
.1
|
|
|
51.5
|
|
|
—
|
|
|
51.6
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
4.9
|
|
|
—
|
|
|
4.9
|
|
||||
States and political subdivisions
|
—
|
|
|
15.7
|
|
|
—
|
|
|
15.7
|
|
||||
Asset-backed securities
|
—
|
|
|
9.7
|
|
|
—
|
|
|
9.7
|
|
||||
Collateralized debt obligations
|
—
|
|
|
—
|
|
|
3.6
|
|
|
3.6
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
20.7
|
|
|
—
|
|
|
20.7
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
.2
|
|
|
—
|
|
|
.2
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
14.3
|
|
|
—
|
|
|
14.3
|
|
||||
Equity securities
|
.3
|
|
|
1.3
|
|
|
—
|
|
|
1.6
|
|
||||
Total trading securities
|
.4
|
|
|
118.3
|
|
|
3.6
|
|
|
122.3
|
|
||||
Investments held by variable interest entities - corporate securities
|
—
|
|
|
564.7
|
|
|
—
|
|
|
564.7
|
|
||||
Other invested assets:
|
|
|
|
|
|
|
|
||||||||
Company-owned life insurance
|
—
|
|
|
111.2
|
|
|
—
|
|
|
111.2
|
|
||||
Hedge funds
|
—
|
|
|
18.0
|
|
|
—
|
|
|
18.0
|
|
||||
Derivatives
|
.2
|
|
|
88.3
|
|
|
—
|
|
|
88.5
|
|
||||
Total other invested assets
|
.2
|
|
|
217.5
|
|
|
—
|
|
|
217.7
|
|
||||
Cash and cash equivalents - unrestricted:
|
|
|
|
|
|
|
|
||||||||
Cash
|
105.1
|
|
|
—
|
|
|
—
|
|
|
105.1
|
|
||||
Cash equivalents and short-term investments
|
—
|
|
|
68.4
|
|
|
—
|
|
|
68.4
|
|
||||
Total cash and cash equivalents - unrestricted
|
105.1
|
|
|
68.4
|
|
|
—
|
|
|
173.5
|
|
||||
Cash and cash equivalents held by variable interest entities
|
65.8
|
|
|
—
|
|
|
—
|
|
|
65.8
|
|
||||
Assets held in separate accounts
|
—
|
|
|
16.0
|
|
|
—
|
|
|
16.0
|
|
||||
Total assets carried at fair value by category
|
$
|
211.6
|
|
|
$
|
24,179.4
|
|
|
$
|
723.2
|
|
|
$
|
25,114.2
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest-sensitive products - embedded derivatives associated with fixed index annuity products
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
704.3
|
|
|
$
|
704.3
|
|
Interest-sensitive products - embedded derivatives associated with modified coinsurance agreement
|
—
|
|
|
—
|
|
|
3.4
|
|
|
3.4
|
|
||||
Total liabilities for insurance products
|
—
|
|
|
—
|
|
|
707.7
|
|
|
707.7
|
|
||||
Total liabilities carried at fair value by category
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
707.7
|
|
|
$
|
707.7
|
|
|
March 31, 2012
|
|
December 31, 2011
|
||||||||||||||||||||||||
|
Quoted prices in active markets for identical assets or liabilities
(Level 1)
|
|
Significant other observable inputs
(Level 2)
|
|
Significant unobservable inputs
(Level 3)
|
|
Total estimated fair value
|
|
Total carrying amount
|
|
Total estimated fair value
|
|
Total carrying amount
|
||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Mortgage loans
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,662.4
|
|
|
$
|
1,662.4
|
|
|
$
|
1,546.7
|
|
|
$
|
1,735.4
|
|
|
$
|
1,602.8
|
|
Policy loans
|
—
|
|
|
277.8
|
|
|
—
|
|
|
277.8
|
|
|
277.8
|
|
|
279.7
|
|
|
279.7
|
|
|||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Insurance liabilities for interest-sensitive products excluding embedded derivatives (a)
|
—
|
|
|
—
|
|
|
12,395.7
|
|
|
12,395.7
|
|
|
12,395.7
|
|
|
13,165.5
|
|
|
13,165.5
|
|
|||||||
Investment borrowings
|
—
|
|
|
1,737.2
|
|
|
—
|
|
|
1,737.2
|
|
|
1,684.9
|
|
|
1,735.7
|
|
|
1,676.5
|
|
|||||||
Borrowings related to variable interest entities
|
—
|
|
|
495.1
|
|
|
—
|
|
|
495.1
|
|
|
519.9
|
|
|
485.1
|
|
|
519.9
|
|
|||||||
Notes payable – direct corporate obligations
|
—
|
|
|
1,012.0
|
|
|
—
|
|
|
1,012.0
|
|
|
799.3
|
|
|
978.3
|
|
|
857.9
|
|
(a)
|
The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at March 31, 2012. This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.
|
|
Quoted prices in active markets
for identical assets or liabilities
(Level 1)
|
|
Significant other observable
inputs
(Level 2) (a)
|
|
|
|
Significant unobservable inputs
(Level 3) (a)
|
|
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
—
|
|
|
$
|
15,594.4
|
|
|
|
|
$
|
278.1
|
|
|
|
|
$
|
15,872.5
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
303.8
|
|
|
|
|
1.6
|
|
|
|
|
305.4
|
|
||||
States and political subdivisions
|
—
|
|
|
1,952.3
|
|
|
|
|
2.1
|
|
|
|
|
1,954.4
|
|
||||
Debt securities issued by foreign governments
|
—
|
|
|
1.4
|
|
|
|
|
—
|
|
|
|
|
1.4
|
|
||||
Asset-backed securities
|
—
|
|
|
1,334.3
|
|
|
|
|
79.7
|
|
|
|
|
1,414.0
|
|
||||
Collateralized debt obligations
|
—
|
|
|
—
|
|
|
|
|
327.3
|
|
|
|
|
327.3
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
1,415.7
|
|
|
|
|
17.3
|
|
|
|
|
1,433.0
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
29.8
|
|
|
|
|
2.2
|
|
|
|
|
32.0
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
2,051.2
|
|
|
|
|
124.8
|
|
|
|
|
2,176.0
|
|
||||
Total fixed maturities, available for sale
|
—
|
|
|
22,682.9
|
|
|
|
|
833.1
|
|
|
|
|
23,516.0
|
|
||||
Equity securities
|
17.9
|
|
|
87.3
|
|
|
|
|
69.9
|
|
|
|
|
175.1
|
|
||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
—
|
|
|
67.6
|
|
|
|
|
—
|
|
|
|
|
67.6
|
|
||||
United States Treasury securities and obligations of United States government corporations and agencies
|
—
|
|
|
4.9
|
|
|
|
|
—
|
|
|
|
|
4.9
|
|
||||
States and political subdivisions
|
—
|
|
|
15.6
|
|
|
|
|
—
|
|
|
|
|
15.6
|
|
||||
Asset-backed securities
|
—
|
|
|
.1
|
|
|
|
|
—
|
|
|
|
|
.1
|
|
||||
Commercial mortgage-backed securities
|
—
|
|
|
—
|
|
|
|
|
.4
|
|
|
|
|
.4
|
|
||||
Mortgage pass-through securities
|
—
|
|
|
.2
|
|
|
|
|
—
|
|
|
|
|
.2
|
|
||||
Collateralized mortgage obligations
|
—
|
|
|
.7
|
|
|
|
|
—
|
|
|
|
|
.7
|
|
||||
Equity securities
|
.7
|
|
|
1.4
|
|
|
|
|
—
|
|
|
|
|
2.1
|
|
||||
Total trading securities
|
.7
|
|
|
90.5
|
|
|
|
|
.4
|
|
|
|
|
91.6
|
|
||||
Investments held by variable interest entities
|
—
|
|
|
496.3
|
|
|
|
|
—
|
|
|
|
|
496.3
|
|
||||
Other invested assets
|
—
|
|
|
159.9
|
|
|
(b)
|
|
—
|
|
|
|
|
159.9
|
|
||||
Assets held in separate accounts
|
—
|
|
|
15.0
|
|
|
|
|
—
|
|
|
|
|
15.0
|
|
||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest-sensitive products
|
—
|
|
|
—
|
|
|
|
|
669.8
|
|
|
(c)
|
|
669.8
|
|
(a)
|
We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.
|
(b)
|
Includes company-owned life insurance and derivatives.
|
(c)
|
Includes
$666.3 million
of embedded derivatives associated with our fixed index annuity products and
$3.5 million
of embedded derivatives associated with a modified coinsurance agreement.
|
|
March 31, 2012
|
|
|
||||||||||||||||||||||||||||
|
Beginning balance as of December 31, 2011 (a)
|
|
Purchases, sales, issuances and settlements, net (c)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)
|
|
Transfers into Level 3
|
|
Transfers out of Level 3 (b)
|
|
Ending balance as of March 31, 2012
|
|
Amount of total gains (losses) for the three months ended March 31, 2012 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
$
|
278.1
|
|
|
$
|
15.0
|
|
|
$
|
—
|
|
|
$
|
.5
|
|
|
$
|
51.2
|
|
|
$
|
(76.8
|
)
|
|
$
|
268.0
|
|
|
$
|
—
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
1.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.6
|
|
|
—
|
|
||||||||
States and political subdivisions
|
2.1
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|
7.4
|
|
|
—
|
|
|
9.6
|
|
|
—
|
|
||||||||
Asset-backed securities
|
79.7
|
|
|
(8.2
|
)
|
|
(.4
|
)
|
|
(1.3
|
)
|
|
4.7
|
|
|
(51.8
|
)
|
|
22.7
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
327.3
|
|
|
(.8
|
)
|
|
—
|
|
|
5.9
|
|
|
—
|
|
|
—
|
|
|
332.4
|
|
|
—
|
|
||||||||
Commercial mortgage-backed securities
|
17.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(17.3
|
)
|
|
—
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
2.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.2
|
|
|
—
|
|
||||||||
Collateralized mortgage obligations
|
124.8
|
|
|
3.5
|
|
|
—
|
|
|
.1
|
|
|
10.9
|
|
|
(124.6
|
)
|
|
14.7
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
833.1
|
|
|
9.5
|
|
|
(.4
|
)
|
|
5.3
|
|
|
74.2
|
|
|
(270.5
|
)
|
|
651.2
|
|
|
—
|
|
||||||||
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
6.4
|
|
|
—
|
|
|
(3.8
|
)
|
|
.6
|
|
|
—
|
|
|
—
|
|
|
3.2
|
|
|
(3.8
|
)
|
||||||||
Venture capital investments
|
63.5
|
|
|
—
|
|
|
—
|
|
|
1.7
|
|
|
—
|
|
|
—
|
|
|
65.2
|
|
|
—
|
|
||||||||
Total equity securities
|
69.9
|
|
|
—
|
|
|
(3.8
|
)
|
|
2.3
|
|
|
—
|
|
|
—
|
|
|
68.4
|
|
|
(3.8
|
)
|
||||||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Collateralized debt obligations
|
—
|
|
|
3.2
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.6
|
|
|
.4
|
|
||||||||
Commercial mortgage-backed securities
|
.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(.4
|
)
|
|
—
|
|
|
—
|
|
||||||||
Total trading securities
|
.4
|
|
|
3.2
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
(.4
|
)
|
|
3.6
|
|
|
.4
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Interest-sensitive products
|
(669.8
|
)
|
|
(50.5
|
)
|
|
12.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(707.7
|
)
|
|
12.6
|
|
(a)
|
We revised the hierarchy classification of certain fixed maturities, equity securities, trading securities and other invested assets as we believe the observability of the inputs more closely represent Level 2 valuations.
|
(b)
|
For our fixed maturity securities, the majority of our transfers out of Level 3 are the result of obtaining a valuation from an independent pricing service at the end of the period, whereas a broker quote was used as of the beginning of the period.
|
(c)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended
March 31, 2012
(dollars in millions):
|
|
Purchases
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
15.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15.0
|
|
Asset-backed securities
|
—
|
|
|
(8.2
|
)
|
|
—
|
|
|
—
|
|
|
(8.2
|
)
|
|||||
Collateralized debt obligations
|
28.3
|
|
|
(29.1
|
)
|
|
—
|
|
|
—
|
|
|
(.8
|
)
|
|||||
Collateralized mortgage obligations
|
14.4
|
|
|
(10.9
|
)
|
|
—
|
|
|
—
|
|
|
3.5
|
|
|||||
Total fixed maturities, available for sale
|
57.7
|
|
|
(48.2
|
)
|
|
—
|
|
|
—
|
|
|
9.5
|
|
|||||
Trading securities - collateralized debt obligations
|
3.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.2
|
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest-sensitive products
|
(27.3
|
)
|
|
5.0
|
|
|
(38.9
|
)
|
|
10.7
|
|
|
(50.5
|
)
|
|
|
March 31, 2011
|
|
|
||||||||||||||||||||||||||||
|
|
Beginning balance as of December 31, 2010
|
|
Purchases, sales, issuances and settlements, net (a)
|
|
Total realized and unrealized gains (losses) included in net income
|
|
Total realized and unrealized gains (losses) included in other comprehensive income (loss)
|
|
Transfers into Level 3
|
|
Transfers out of Level 3
|
|
Ending balance as of March 31, 2011
|
|
Amount of total gains (losses) for the three months ended March 31, 2011 included in our net income relating to assets and liabilities still held as of the reporting date
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Corporate securities
|
|
$
|
1,907.8
|
|
|
$
|
(63.2
|
)
|
|
$
|
(11.8
|
)
|
|
$
|
9.1
|
|
|
$
|
11.2
|
|
|
$
|
—
|
|
|
$
|
1,853.1
|
|
|
$
|
6.4
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
|
2.0
|
|
|
—
|
|
|
—
|
|
|
(.3
|
)
|
|
—
|
|
|
—
|
|
|
1.7
|
|
|
—
|
|
||||||||
States and political subdivisions
|
|
2.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
||||||||
Asset-backed securities
|
|
182.3
|
|
|
(1.8
|
)
|
|
—
|
|
|
(.5
|
)
|
|
27.4
|
|
|
—
|
|
|
207.4
|
|
|
—
|
|
||||||||
Collateralized debt obligations
|
|
256.5
|
|
|
(76.7
|
)
|
|
2.1
|
|
|
4.3
|
|
|
—
|
|
|
—
|
|
|
186.2
|
|
|
—
|
|
||||||||
Mortgage pass-through securities
|
|
3.5
|
|
|
(.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.3
|
|
|
—
|
|
||||||||
Collateralized mortgage obligations
|
|
197.1
|
|
|
11.5
|
|
|
—
|
|
|
1.7
|
|
|
90.9
|
|
|
(53.7
|
)
|
|
247.5
|
|
|
—
|
|
||||||||
Total fixed maturities, available for sale
|
|
2,551.7
|
|
|
(130.4
|
)
|
|
(9.7
|
)
|
|
14.3
|
|
|
129.5
|
|
|
(56.2
|
)
|
|
2,499.2
|
|
|
6.4
|
|
||||||||
Equity securities
|
|
7.6
|
|
|
37.5
|
|
|
(.8
|
)
|
|
.7
|
|
|
—
|
|
|
—
|
|
|
45.0
|
|
|
—
|
|
||||||||
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Collateralized mortgage obligations
|
|
.4
|
|
|
—
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.5
|
|
|
.1
|
|
||||||||
Total trading securities
|
|
.4
|
|
|
—
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.5
|
|
|
.1
|
|
||||||||
Investments held by variable interest entities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
|
6.7
|
|
|
(7.9
|
)
|
|
1.5
|
|
|
(.3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Interest-sensitive products
|
|
(553.2
|
)
|
|
(36.1
|
)
|
|
1.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(587.5
|
)
|
|
1.8
|
|
(a)
|
Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period. Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the three months ended
March 31, 2011
(dollars in millions):
|
|
Purchases
|
|
Sales
|
|
Issuances
|
|
Settlements
|
|
Purchases, sales, issuances and settlements, net
|
||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
||||||||||
Fixed maturities, available for sale:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
$
|
45.0
|
|
|
$
|
(108.2
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(63.2
|
)
|
Asset-backed securities
|
—
|
|
|
(1.8
|
)
|
|
—
|
|
|
—
|
|
|
(1.8
|
)
|
|||||
Collateralized debt obligations
|
1.7
|
|
|
(78.4
|
)
|
|
—
|
|
|
—
|
|
|
(76.7
|
)
|
|||||
Mortgage pass-through securities
|
—
|
|
|
(.2
|
)
|
|
—
|
|
|
—
|
|
|
(.2
|
)
|
|||||
Collateralized mortgage obligations
|
18.4
|
|
|
(6.9
|
)
|
|
—
|
|
|
—
|
|
|
11.5
|
|
|||||
Total fixed maturities, available for sale
|
65.1
|
|
|
(195.5
|
)
|
|
—
|
|
|
—
|
|
|
(130.4
|
)
|
|||||
Equity securities
|
37.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
37.5
|
|
|||||
Investments held by variable interest entities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Corporate securities
|
—
|
|
|
(7.9
|
)
|
|
—
|
|
|
—
|
|
|
(7.9
|
)
|
|||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities for insurance products:
|
|
|
|
|
|
|
|
|
|
||||||||||
Interest-sensitive products
|
(25.0
|
)
|
|
2.6
|
|
|
(19.0
|
)
|
|
5.3
|
|
|
(36.1
|
)
|
|
Fair Value at March 31, 2012
|
|
Valuation Technique(s)
|
|
Unobservable Inputs
|
|
Range (Weighted Average)
|
||
Assets:
|
|
|
|
|
|
|
|
||
Corporate securities (a)
|
$
|
175.7
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
1.90% - 6.50% (3.49%)
|
Asset-backed securities (b)
|
11.2
|
|
|
Discounted cash flow analysis
|
|
Discount margins
|
|
2.16% - 2.32% (2.31%)
|
|
Collateralized debt obligations (c)
|
336.0
|
|
|
Discounted cash flow analysis
|
|
Recoveries
|
|
58% - 66% (ramp over 6 months)
|
|
|
|
|
|
|
Constant prepayment rate
|
|
20%
|
||
|
|
|
|
|
Discount margins
|
|
1.70% - 12.10% (3.32%)
|
||
|
|
|
|
|
Annual default rate
|
|
.95% - 5.95% (3.01%)
|
||
|
|
|
|
|
Portfolio CCC %
|
|
1.80% - 21.41% (11.67%)
|
||
Equity securities (d)
|
3.2
|
|
|
Discounted cash flow analysis
|
|
Earnings multiple of capital and surplus
|
|
.18 -.37 (.308)
|
|
Venture capital investments (e)
|
65.2
|
|
|
Market multiples
|
|
EBITDA multiple
|
|
3.9 - 45.1 (12.69)
|
|
|
|
|
|
|
Revenue multiple
|
|
0.6 - 6.9 (4.38)
|
||
|
|
|
|
|
Book equity multiple
|
|
1.0 - 5.8 (1)
|
||
Other assets categorized as Level 3 (f)
|
131.9
|
|
|
Unadjusted third-party price source
|
|
Not applicable
|
|
Not applicable
|
|
Total
|
723.2
|
|
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
||
Interest sensitive products (g)
|
707.7
|
|
|
Discounted projected embedded derivatives
|
|
Projected portfolio yields
|
|
5.35% - 5.61% (5.55%)
|
|
|
|
|
|
|
Discount rates
|
|
0.0 - 4.3% (1.8%)
|
||
|
|
|
|
|
Surrender rates
|
|
4% - 43% (19%)
|
(a)
|
Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(b)
|
Asset-backed securities - The significant unobservable input used in the fair value measurement of our asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.
|
(c)
|
Collateralized debt obligations - The significant unobservable inputs used in the fair value measurement of our collateralized debt obligations relate to collateral performance, including default rate, recoveries and constant prepayment rate, as well as discount margins of the underlying collateral. Significant increases (decreases) in default rate in isolation would result in a significantly lower (higher) fair value measurement. Generally, a significant increase (decrease) in the constant prepayment rate and recoveries in isolation would result in a significantly higher (lower) fair value measurement. Generally a significant increase (decrease) in discount margin in isolation would result in a significantly lower (higher) fair value measurement. Generally, a change in the assumption used for the annual default rate is accompanied by a directionally similar change in the assumption used for discount margins and portfolio CCC % and a directionally opposite change in the assumption used for constant prepayment rate and recoveries. A tranche's payment priority and investment cost basis could alter generalized fair value outcomes.
|
(d)
|
Equity securities - The significant unobservable input used in the fair value measurement of our securities is the earnings multiple of capital and surplus. Significant increases (decreases) in the earnings multiple of the capital and surplus in isolation would result in a significantly higher (lower) fair value measurement.
|
(e)
|
Venture capital investments - The significant unobservable inputs used in the fair value measurement of our venture capital investments are the EBITDA multiple and revenue multiple. Generally, a significant increase (decrease) in the EBITDA or revenue multiples in isolation would result in a significantly higher (lower) fair value measurement.
|
(f)
|
Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.
|
(g)
|
Interest sensitive products - The significant unobservable inputs used in the fair value measurement of our interest sensitive products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.
|
ITEM 2.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
|
•
|
changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products;
|
•
|
general economic, market and political conditions, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;
|
•
|
the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
|
•
|
our ability to make anticipated changes to certain NGEs of our life insurance products;
|
•
|
our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;
|
•
|
the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;
|
•
|
mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;
|
•
|
changes in our assumptions related to deferred acquisition costs or the present value of future profits;
|
•
|
the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;
|
•
|
our assumption that the positions we take on our tax return filings, including our position that our 7.0% Debentures will not be treated as stock for purposes of Section 382 of the Code and will not trigger an ownership change, will not be successfully challenged by the IRS;
|
•
|
changes in accounting principles and the interpretation thereof (including changes in principles related to accounting for deferred acquisition costs);
|
•
|
our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;
|
•
|
our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in
|
•
|
performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges);
|
•
|
our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
|
•
|
our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;
|
•
|
our ability to maintain effective controls over financial reporting;
|
•
|
our ability to continue to recruit and retain productive agents and distribution partners and customer response to new products, distribution channels and marketing initiatives;
|
•
|
our ability to achieve eventual upgrades of the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;
|
•
|
the risk factors or uncertainties listed from time to time in our filings with the SEC;
|
•
|
regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends and surplus debenture interest to us, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products; and
|
•
|
changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets.
|
•
|
Bankers Life,
which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents and sales managers supported by a network of community-based branch offices. The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company. Bankers Life also markets and distributes Medicare Advantage plans primarily through a distribution arrangement with Humana, Inc. ("Humana") and Medicare Part D prescription drug plans through a distribution and reinsurance arrangement with Coventry.
|
•
|
Washington National,
which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the
|
•
|
Colonial Penn
, which markets primarily graded benefit and simplified issue life insurance directly to customers through television advertising, direct mail, the internet and telemarketing. The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company.
|
•
|
Other CNO Business,
which consists of blocks of interest-sensitive life insurance, traditional life insurance, annuities, long-term care insurance and other supplemental health products. These blocks of business are not being actively marketed and were primarily issued or acquired by Conseco Life Insurance Company and Washington National Insurance Company.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Earnings before net realized investment gains, fair value changes in embedded derivative liabilities, corporate interest expense, loss on extinguishment of debt and income taxes (“EBIT” a non-GAAP financial measure) (a):
|
|
|
|
||||
Bankers Life
|
$
|
70.5
|
|
|
$
|
62.2
|
|
Washington National
|
24.7
|
|
|
24.3
|
|
||
Colonial Penn
|
(9.8
|
)
|
|
(5.7
|
)
|
||
Other CNO Business
|
(2.3
|
)
|
|
7.4
|
|
||
EBIT from business segments
|
83.1
|
|
|
88.2
|
|
||
Corporate Operations, excluding corporate interest expense
|
(1.8
|
)
|
|
(.5
|
)
|
||
EBIT
|
81.3
|
|
|
87.7
|
|
||
Corporate interest expense
|
(17.5
|
)
|
|
(20.6
|
)
|
||
Income before loss on extinguishment of debt, net realized investment gains, fair value changes in embedded derivative liabilities and taxes
|
63.8
|
|
|
67.1
|
|
||
Tax expense on operating income
|
23.2
|
|
|
23.9
|
|
||
Net operating income
|
40.6
|
|
|
43.2
|
|
||
Net realized investment gains (net of related amortization and taxes)
|
14.1
|
|
|
3.1
|
|
||
Fair value changes in embedded derivative liabilities (net of related amortization and taxes)
|
4.5
|
|
|
—
|
|
||
Loss on extinguishment of debt, net of income taxes
|
(.1
|
)
|
|
(.9
|
)
|
||
Net income
|
$
|
59.1
|
|
|
$
|
45.4
|
|
Per diluted share:
|
|
|
|
|
|||
Net operating income
|
$
|
.15
|
|
|
$
|
.15
|
|
Net realized investment gains, net of related amortization and taxes
|
.05
|
|
|
.01
|
|
||
Fair value changes in embedded derivative liabilities, net of related amortization and taxes
|
.01
|
|
|
—
|
|
||
Net income
|
$
|
.21
|
|
|
$
|
.16
|
|
(a)
|
Management believes that an analysis of EBIT provides a clearer comparison of the operating results of the Company from period to period because it excludes: (i) corporate interest expense; (ii) loss on extinguishment of debt; (iii) net realized investment gains; and (iv) fair value changes in embedded derivative liabilities that are unrelated to the Company’s underlying fundamentals. Net realized investment gains or losses include: (i) gains or losses on the sales of investments; (ii) other-than-temporary impairments recognized through net income; and (iii) changes in fair value of certain fixed maturity investments with embedded derivatives. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Income (loss) before net realized investment gains (losses) and fair value changes in embedded derivative liabilities, net of related amortization and income taxes (a non-GAAP measure) (a):
|
|
|
|
||||
Bankers Life
|
$
|
70.5
|
|
|
$
|
62.2
|
|
Washington National
|
24.7
|
|
|
24.3
|
|
||
Colonial Penn
|
(9.8
|
)
|
|
(5.7
|
)
|
||
Other CNO Business
|
(2.3
|
)
|
|
7.4
|
|
||
Corporate operations
|
(19.5
|
)
|
|
(22.5
|
)
|
||
|
63.6
|
|
|
65.7
|
|
||
Net realized investment gains (losses), net of related amortization:
|
|
|
|
||||
Bankers Life
|
9.7
|
|
|
5.8
|
|
||
Washington National
|
3.1
|
|
|
(.5
|
)
|
||
Colonial Penn
|
2.6
|
|
|
1.1
|
|
||
Other CNO Business
|
6.5
|
|
|
(.6
|
)
|
||
Corporate operations
|
(.1
|
)
|
|
(1.1
|
)
|
||
|
21.8
|
|
|
4.7
|
|
||
Fair value changes in embedded derivative liabilities, net of related amortization:
|
|
|
|
||||
Bankers Life
|
6.8
|
|
|
—
|
|
||
Other CNO Business
|
.1
|
|
|
—
|
|
||
|
6.9
|
|
|
—
|
|
||
Income (loss) before income taxes:
|
|
|
|
||||
Bankers Life
|
87.0
|
|
|
68.0
|
|
||
Washington National
|
27.8
|
|
|
23.8
|
|
||
Colonial Penn
|
(7.2
|
)
|
|
(4.6
|
)
|
||
Other CNO Business
|
4.3
|
|
|
6.8
|
|
||
Corporate operations
|
(19.6
|
)
|
|
(23.6
|
)
|
||
Income before income taxes
|
$
|
92.3
|
|
|
$
|
70.4
|
|
(a)
|
These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude net realized investment gains (losses) and fair value of embedded derivative liabilities, net of related amortization and before income taxes. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premium collections:
|
|
|
|
||||
Annuities
|
$
|
184.7
|
|
|
$
|
222.2
|
|
Medicare supplement and other supplemental health
|
329.5
|
|
|
337.6
|
|
||
Life
|
70.1
|
|
|
56.4
|
|
||
Total collections
|
$
|
584.3
|
|
|
$
|
616.2
|
|
Average liabilities for insurance products:
|
|
|
|
||||
Annuities:
|
|
|
|
||||
Mortality based
|
$
|
233.8
|
|
|
$
|
245.9
|
|
Fixed index
|
2,707.4
|
|
|
2,147.7
|
|
||
Deposit based
|
4,644.9
|
|
|
4,832.4
|
|
||
Medicare supplement and other supplemental health
|
4,634.5
|
|
|
4,489.6
|
|
||
Life:
|
|
|
|
||||
Interest sensitive
|
441.4
|
|
|
420.5
|
|
||
Non-interest sensitive
|
483.0
|
|
|
397.8
|
|
||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
13,145.0
|
|
|
$
|
12,533.9
|
|
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
406.5
|
|
|
$
|
400.0
|
|
Net investment income:
|
|
|
|
||||
General account invested assets
|
200.3
|
|
|
191.3
|
|
||
Fixed index products
|
34.6
|
|
|
18.3
|
|
||
Fee revenue and other income
|
2.9
|
|
|
2.3
|
|
||
Total revenues
|
644.3
|
|
|
611.9
|
|
||
Expenses:
|
|
|
|
||||
Insurance policy benefits
|
335.2
|
|
|
337.6
|
|
||
Amounts added to policyholder account balances:
|
|
|
|
||||
Annuity products and interest-sensitive life products other than fixed index products
|
38.5
|
|
|
40.8
|
|
||
Fixed index products
|
47.2
|
|
|
26.4
|
|
||
Amortization related to operations
|
56.9
|
|
|
68.5
|
|
||
Interest expense on investment borrowings
|
1.4
|
|
|
1.2
|
|
||
Other operating costs and expenses
|
94.6
|
|
|
75.2
|
|
||
Total benefits and expenses
|
573.8
|
|
|
549.7
|
|
||
Income before net realized investment gains and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
70.5
|
|
|
62.2
|
|
||
Net realized investment gains
|
10.6
|
|
|
6.6
|
|
||
Amortization related to net realized investment gains
|
(.9
|
)
|
|
(.8
|
)
|
||
Net realized investment gains, net of related amortization
|
9.7
|
|
|
5.8
|
|
||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
11.0
|
|
|
—
|
|
||
Amortization related to fair value changes in embedded derivative liabilities
|
(4.2
|
)
|
|
—
|
|
||
Fair value changes in embedded derivative liabilities, net of related amortization
|
6.8
|
|
|
—
|
|
||
Income before income taxes
|
$
|
87.0
|
|
|
$
|
68.0
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Health benefit ratios:
|
|
|
|
||||
All health lines:
|
|
|
|
||||
Insurance policy benefits
|
$
|
282.8
|
|
|
$
|
297.6
|
|
Benefit ratio (a)
|
84.6
|
%
|
|
87.6
|
%
|
||
Medicare supplement:
|
|
|
|
||||
Insurance policy benefits
|
$
|
117.8
|
|
|
$
|
121.7
|
|
Benefit ratio (a)
|
64.5
|
%
|
|
67.2
|
%
|
||
PDP:
|
|
|
|
||||
Insurance policy benefits
|
$
|
9.2
|
|
|
$
|
12.9
|
|
Benefit ratio (a)
|
85.9
|
%
|
|
89.5
|
%
|
||
PFFS:
|
|
|
|
||||
Insurance policy benefits
|
$
|
(.1
|
)
|
|
$
|
(.7
|
)
|
Benefit ratio (a)
|
N/A
|
|
|
N/A
|
|
||
Long-term care:
|
|
|
|
||||
Insurance policy benefits
|
$
|
155.9
|
|
|
$
|
163.7
|
|
Benefit ratio (a)
|
110.9
|
%
|
|
113.4
|
%
|
||
Interest-adjusted benefit ratio (b)
|
65.5
|
%
|
|
70.8
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life’s long-term care products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Expenses related to the marketing and quota-share agreements with Coventry
|
$
|
1.9
|
|
|
$
|
2.0
|
|
Commission expense and agent manager benefits
|
14.0
|
|
|
13.8
|
|
||
Other operating expenses
|
78.7
|
|
|
59.4
|
|
||
Total
|
$
|
94.6
|
|
|
$
|
75.2
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premium collections:
|
|
|
|
||||
Medicare supplement and other supplemental health
|
$
|
141.7
|
|
|
$
|
143.2
|
|
Life
|
4.0
|
|
|
4.3
|
|
||
Total collections
|
$
|
145.7
|
|
|
$
|
147.5
|
|
Average liabilities for insurance products:
|
|
|
|
||||
Medicare supplement and other supplemental health
|
$
|
2,429.6
|
|
|
$
|
2,434.6
|
|
Non-interest sensitive life
|
200.4
|
|
|
205.2
|
|
||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
2,630.0
|
|
|
$
|
2,639.8
|
|
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
147.4
|
|
|
$
|
145.4
|
|
Net investment income:
|
|
|
|
||||
General account invested assets
|
50.0
|
|
|
46.3
|
|
||
Trading account income related to reinsurer accounts
|
.1
|
|
|
.3
|
|
||
Change in value of embedded derivatives related to modified coinsurance agreements
|
(.1
|
)
|
|
(.3
|
)
|
||
Fee revenue and other income
|
.2
|
|
|
.3
|
|
||
Total revenues
|
197.6
|
|
|
192.0
|
|
||
Expenses:
|
|
|
|
||||
Insurance policy benefits
|
115.7
|
|
|
112.2
|
|
||
Amortization related to operations
|
12.7
|
|
|
13.4
|
|
||
Interest expense on investment borrowings
|
.7
|
|
|
—
|
|
||
Other operating costs and expenses
|
43.8
|
|
|
42.1
|
|
||
Total benefits and expenses
|
172.9
|
|
|
167.7
|
|
||
Income before net realized investment gains (losses) and income taxes
|
24.7
|
|
|
24.3
|
|
||
Net realized investment gains (losses)
|
3.1
|
|
|
(.5
|
)
|
||
Income before income taxes
|
$
|
27.8
|
|
|
$
|
23.8
|
|
Health benefit ratios:
|
|
|
|
||||
Medicare supplement:
|
|
|
|
||||
Insurance policy benefits
|
$
|
20.1
|
|
|
$
|
23.5
|
|
Benefit ratio (a)
|
65.4
|
%
|
|
66.3
|
%
|
||
Supplemental health:
|
|
|
|
||||
Insurance policy benefits
|
$
|
92.0
|
|
|
$
|
82.4
|
|
Benefit ratio (a)
|
82.4
|
%
|
|
78.7
|
%
|
||
Interest-adjusted benefit ratio (b)
|
55.1
|
%
|
|
49.1
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Washington National’s supplemental health products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premium collections:
|
|
|
|
||||
Life
|
$
|
52.6
|
|
|
$
|
49.4
|
|
Supplemental health
|
1.3
|
|
|
1.5
|
|
||
Total collections
|
$
|
53.9
|
|
|
$
|
50.9
|
|
Average liabilities for insurance products:
|
|
|
|
||||
Annuities-mortality based
|
$
|
77.0
|
|
|
$
|
78.5
|
|
Supplemental health
|
15.4
|
|
|
16.6
|
|
||
Life:
|
|
|
|
||||
Interest sensitive
|
19.9
|
|
|
20.7
|
|
||
Non-interest sensitive
|
598.4
|
|
|
586.7
|
|
||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
710.7
|
|
|
$
|
702.5
|
|
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
53.4
|
|
|
$
|
50.3
|
|
Net investment income:
|
|
|
|
||||
General account invested assets
|
10.0
|
|
|
10.3
|
|
||
Fee revenue and other income
|
.2
|
|
|
.2
|
|
||
Total revenues
|
63.6
|
|
|
60.8
|
|
||
Expenses:
|
|
|
|
||||
Insurance policy benefits
|
41.9
|
|
|
38.5
|
|
||
Amounts added to annuity and interest-sensitive life product account balances
|
.2
|
|
|
.2
|
|
||
Amortization related to operations
|
3.7
|
|
|
4.0
|
|
||
Other operating costs and expenses
|
27.6
|
|
|
23.8
|
|
||
Total benefits and expenses
|
73.4
|
|
|
66.5
|
|
||
Income (loss) before net realized investment gains and income taxes
|
(9.8
|
)
|
|
(5.7
|
)
|
||
Net realized investment gains
|
2.6
|
|
|
1.1
|
|
||
Income (loss) before income taxes
|
$
|
(7.2
|
)
|
|
$
|
(4.6
|
)
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premium collections:
|
|
|
|
||||
Annuities
|
$
|
.9
|
|
|
$
|
4.2
|
|
Other health
|
6.9
|
|
|
7.6
|
|
||
Life
|
45.3
|
|
|
46.4
|
|
||
Total collections
|
$
|
53.1
|
|
|
$
|
58.2
|
|
Average liabilities for insurance products:
|
|
|
|
||||
Annuities:
|
|
|
|
||||
Mortality based
|
$
|
229.1
|
|
|
$
|
207.8
|
|
Fixed index
|
553.8
|
|
|
652.1
|
|
||
Deposit based
|
638.4
|
|
|
692.0
|
|
||
Separate accounts
|
15.5
|
|
|
17.8
|
|
||
Other health
|
481.0
|
|
|
481.8
|
|
||
Life:
|
|
|
|
||||
Interest sensitive
|
2,416.9
|
|
|
2,527.4
|
|
||
Non-interest sensitive
|
766.5
|
|
|
805.6
|
|
||
Total average liabilities for insurance products, net of reinsurance ceded
|
$
|
5,101.2
|
|
|
$
|
5,384.5
|
|
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
79.0
|
|
|
$
|
71.5
|
|
Net investment income:
|
|
|
|
||||
General account invested assets
|
84.0
|
|
|
88.2
|
|
||
Fixed index products
|
6.8
|
|
|
5.0
|
|
||
Trading account income related to policyholder accounts
|
1.9
|
|
|
1.5
|
|
||
Total revenues
|
171.7
|
|
|
166.2
|
|
||
Expenses:
|
|
|
|
||||
Insurance policy benefits
|
83.0
|
|
|
88.8
|
|
||
Amounts added to policyholder account balances:
|
|
|
|
||||
Annuity products and interest-sensitive life products other than fixed index products
|
29.7
|
|
|
31.6
|
|
||
Fixed index products
|
9.2
|
|
|
7.1
|
|
||
Amortization related to operations
|
7.5
|
|
|
8.6
|
|
||
Interest expense on investment borrowings
|
5.1
|
|
|
4.9
|
|
||
Other operating costs and expenses
|
39.5
|
|
|
17.8
|
|
||
Total benefits and expenses
|
174.0
|
|
|
158.8
|
|
||
Income (loss) before net realized investment losses and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes
|
(2.3
|
)
|
|
7.4
|
|
||
Net realized investment gains (losses)
|
6.7
|
|
|
(1.0
|
)
|
||
Amortization related to net realized investment gains (losses)
|
(.2
|
)
|
|
.4
|
|
||
Net realized investment gains (losses), net of related amortization
|
6.5
|
|
|
(.6
|
)
|
||
Insurance policy benefits - fair value changes in embedded derivative liabilities
|
.6
|
|
|
—
|
|
||
Amortization related to fair value changes in embedded derivative liabilities
|
(.5
|
)
|
|
—
|
|
||
Fair value changes in embedded derivative liabilities, net of related amortization
|
.1
|
|
|
—
|
|
||
Income (loss) before income taxes
|
$
|
4.3
|
|
|
$
|
6.8
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Health benefit ratios:
|
|
|
|
||||
Long-term care:
|
|
|
|
||||
Insurance policy benefits
|
$
|
15.1
|
|
|
$
|
17.2
|
|
Benefit ratio (a)
|
227.4
|
%
|
|
235.7
|
%
|
||
Interest-adjusted benefit ratio (b)
|
122.0
|
%
|
|
148.0
|
%
|
(a)
|
We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.
|
(b)
|
We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Other CNO Business long-term care products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Corporate operations:
|
|
|
|
||||
Interest expense on corporate debt
|
$
|
(17.5
|
)
|
|
$
|
(20.6
|
)
|
Net investment income (loss):
|
|
|
|
||||
General account invested assets
|
.9
|
|
|
—
|
|
||
Other special-purpose portfolios
|
16.2
|
|
|
8.2
|
|
||
Fee revenue and other income
|
.4
|
|
|
.4
|
|
||
Net operating results of variable interest entities
|
2.2
|
|
|
2.0
|
|
||
Interest expense on investment borrowings
|
(.1
|
)
|
|
—
|
|
||
Loss on extinguishment of debt
|
(.2
|
)
|
|
(1.4
|
)
|
||
Other operating costs and expenses
|
(21.4
|
)
|
|
(11.1
|
)
|
||
Loss before net realized investment losses and income taxes
|
(19.5
|
)
|
|
(22.5
|
)
|
||
Net realized investment gains (losses)
|
(.1
|
)
|
|
(1.1
|
)
|
||
Loss before income taxes
|
$
|
(19.6
|
)
|
|
$
|
(23.6
|
)
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
EBIT from In-Force Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
597.0
|
|
|
$
|
584.0
|
|
Net investment income and other
|
377.8
|
|
|
351.7
|
|
||
Total revenues
|
974.8
|
|
|
935.7
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
635.3
|
|
|
624.8
|
|
||
Amortization
|
73.1
|
|
|
85.3
|
|
||
Other expenses
|
137.5
|
|
|
96.2
|
|
||
Total benefits and expenses
|
845.9
|
|
|
806.3
|
|
||
EBIT from In-Force Business
|
$
|
128.9
|
|
|
$
|
129.4
|
|
|
|
|
|
||||
EBIT from New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
89.3
|
|
|
$
|
83.2
|
|
Net investment income and other
|
13.1
|
|
|
12.0
|
|
||
Total revenues
|
102.4
|
|
|
95.2
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
65.3
|
|
|
58.4
|
|
||
Amortization
|
7.7
|
|
|
9.2
|
|
||
Other expenses
|
75.2
|
|
|
68.8
|
|
||
Total benefits and expenses
|
148.2
|
|
|
136.4
|
|
||
EBIT from New Business
|
$
|
(45.8
|
)
|
|
$
|
(41.2
|
)
|
|
|
|
|
||||
EBIT from In-Force and New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
686.3
|
|
|
$
|
667.2
|
|
Net investment income and other
|
390.9
|
|
|
363.7
|
|
||
Total revenues
|
1,077.2
|
|
|
1,030.9
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
700.6
|
|
|
683.2
|
|
||
Amortization
|
80.8
|
|
|
94.5
|
|
||
Other expenses
|
212.7
|
|
|
165.0
|
|
||
Total benefits and expenses
|
994.1
|
|
|
942.7
|
|
||
EBIT from In-Force and New Business
|
$
|
83.1
|
|
|
$
|
88.2
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
EBIT from In-Force Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
341.8
|
|
|
$
|
338.8
|
|
Net investment income and other
|
224.7
|
|
|
199.9
|
|
||
Total revenues
|
566.5
|
|
|
538.7
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
367.4
|
|
|
356.9
|
|
||
Amortization
|
50.0
|
|
|
60.1
|
|
||
Other expenses
|
52.0
|
|
|
35.0
|
|
||
Total benefits and expenses
|
469.4
|
|
|
452.0
|
|
||
EBIT from In-Force Business
|
$
|
97.1
|
|
|
$
|
86.7
|
|
|
|
|
|
||||
EBIT from New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
64.7
|
|
|
$
|
61.2
|
|
Net investment income and other
|
13.1
|
|
|
12.0
|
|
||
Total revenues
|
77.8
|
|
|
73.2
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
53.5
|
|
|
47.9
|
|
||
Amortization
|
6.9
|
|
|
8.4
|
|
||
Other expenses
|
44.0
|
|
|
41.4
|
|
||
Total benefits and expenses
|
104.4
|
|
|
97.7
|
|
||
EBIT from New Business
|
$
|
(26.6
|
)
|
|
$
|
(24.5
|
)
|
|
|
|
|
||||
EBIT from In-Force and New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
406.5
|
|
|
$
|
400.0
|
|
Net investment income and other
|
237.8
|
|
|
211.9
|
|
||
Total revenues
|
644.3
|
|
|
611.9
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
420.9
|
|
|
404.8
|
|
||
Amortization
|
56.9
|
|
|
68.5
|
|
||
Other expenses
|
96.0
|
|
|
76.4
|
|
||
Total benefits and expenses
|
573.8
|
|
|
549.7
|
|
||
EBIT from In-Force and New Business
|
$
|
70.5
|
|
|
$
|
62.2
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
EBIT from In-Force Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
133.0
|
|
|
$
|
131.9
|
|
Net investment income and other
|
50.2
|
|
|
46.6
|
|
||
Total revenues
|
183.2
|
|
|
178.5
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
109.8
|
|
|
106.6
|
|
||
Amortization
|
12.0
|
|
|
12.7
|
|
||
Other expenses
|
34.0
|
|
|
31.9
|
|
||
Total benefits and expenses
|
155.8
|
|
|
151.2
|
|
||
EBIT from In-Force Business
|
$
|
27.4
|
|
|
$
|
27.3
|
|
|
|
|
|
||||
EBIT from New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
14.4
|
|
|
$
|
13.5
|
|
Net investment income and other
|
—
|
|
|
—
|
|
||
Total revenues
|
14.4
|
|
|
13.5
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
5.9
|
|
|
5.6
|
|
||
Amortization
|
.7
|
|
|
.7
|
|
||
Other expenses
|
10.5
|
|
|
10.2
|
|
||
Total benefits and expenses
|
17.1
|
|
|
16.5
|
|
||
EBIT from New Business
|
$
|
(2.7
|
)
|
|
$
|
(3.0
|
)
|
|
|
|
|
||||
EBIT from In-Force and New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
147.4
|
|
|
$
|
145.4
|
|
Net investment income and other
|
50.2
|
|
|
46.6
|
|
||
Total revenues
|
197.6
|
|
|
192.0
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
115.7
|
|
|
112.2
|
|
||
Amortization
|
12.7
|
|
|
13.4
|
|
||
Other expenses
|
44.5
|
|
|
42.1
|
|
||
Total benefits and expenses
|
172.9
|
|
|
167.7
|
|
||
EBIT from In-Force and New Business
|
$
|
24.7
|
|
|
$
|
24.3
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
EBIT from In-Force Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
43.2
|
|
|
$
|
41.8
|
|
Net investment income and other
|
10.2
|
|
|
10.5
|
|
||
Total revenues
|
53.4
|
|
|
52.3
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
36.2
|
|
|
33.8
|
|
||
Amortization
|
3.6
|
|
|
3.9
|
|
||
Other expenses
|
6.9
|
|
|
6.6
|
|
||
Total benefits and expenses
|
46.7
|
|
|
44.3
|
|
||
EBIT from In-Force Business
|
$
|
6.7
|
|
|
$
|
8.0
|
|
|
|
|
|
||||
EBIT from New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
10.2
|
|
|
$
|
8.5
|
|
Net investment income and other
|
—
|
|
|
—
|
|
||
Total revenues
|
10.2
|
|
|
8.5
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
5.9
|
|
|
4.9
|
|
||
Amortization
|
.1
|
|
|
.1
|
|
||
Other expenses
|
20.7
|
|
|
17.2
|
|
||
Total benefits and expenses
|
26.7
|
|
|
22.2
|
|
||
EBIT from New Business
|
$
|
(16.5
|
)
|
|
$
|
(13.7
|
)
|
|
|
|
|
||||
EBIT from In-Force and New Business
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
53.4
|
|
|
$
|
50.3
|
|
Net investment income and other
|
10.2
|
|
|
10.5
|
|
||
Total revenues
|
63.6
|
|
|
60.8
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
42.1
|
|
|
38.7
|
|
||
Amortization
|
3.7
|
|
|
4.0
|
|
||
Other expenses
|
27.6
|
|
|
23.8
|
|
||
Total benefits and expenses
|
73.4
|
|
|
66.5
|
|
||
EBIT from In-Force and New Business
|
$
|
(9.8
|
)
|
|
$
|
(5.7
|
)
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
EBIT from In-Force Business (a)
|
|
|
|
||||
Revenues:
|
|
|
|
||||
Insurance policy income
|
$
|
79.0
|
|
|
$
|
71.5
|
|
Net investment income and other
|
92.7
|
|
|
94.7
|
|
||
Total revenues
|
171.7
|
|
|
166.2
|
|
||
Benefits and expenses:
|
|
|
|
||||
Insurance policy benefits
|
121.9
|
|
|
127.5
|
|
||
Amortization
|
7.5
|
|
|
8.6
|
|
||
Other expenses
|
44.6
|
|
|
22.7
|
|
||
Total benefits and expenses
|
174.0
|
|
|
158.8
|
|
||
EBIT from In-Force Business
|
$
|
(2.3
|
)
|
|
$
|
7.4
|
|
(a)
|
All activity on the Other CNO Business segment relates to in-force business.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premiums collected by product:
|
|
|
|
||||
Annuities:
|
|
|
|
||||
Fixed index (first-year)
|
$
|
134.9
|
|
|
$
|
148.2
|
|
Other fixed rate (first-year)
|
47.8
|
|
|
73.1
|
|
||
Other fixed rate (renewal)
|
2.0
|
|
|
.9
|
|
||
Subtotal - other fixed rate annuities
|
49.8
|
|
|
74.0
|
|
||
Total annuities
|
184.7
|
|
|
222.2
|
|
||
Health:
|
|
|
|
||||
Medicare supplement (first-year)
|
23.8
|
|
|
25.1
|
|
||
Medicare supplement (renewal)
|
151.1
|
|
|
153.7
|
|
||
Subtotal - Medicare supplement
|
174.9
|
|
|
178.8
|
|
||
Long-term care (first-year)
|
5.5
|
|
|
6.1
|
|
||
Long-term care (renewal)
|
131.2
|
|
|
138.8
|
|
||
Subtotal - long-term care
|
136.7
|
|
|
144.9
|
|
||
PDP (first year)
|
.3
|
|
|
.4
|
|
||
PDP (renewal)
|
15.0
|
|
|
10.6
|
|
||
Subtotal – PDP
|
15.3
|
|
|
11.0
|
|
||
Other health (first-year)
|
.4
|
|
|
.4
|
|
||
Other health (renewal)
|
2.2
|
|
|
2.5
|
|
||
Subtotal - other health
|
2.6
|
|
|
2.9
|
|
||
Total health
|
329.5
|
|
|
337.6
|
|
||
Life insurance:
|
|
|
|
||||
First-year
|
32.8
|
|
|
24.7
|
|
||
Renewal
|
37.3
|
|
|
31.7
|
|
||
Total life insurance
|
70.1
|
|
|
56.4
|
|
||
Collections on insurance products:
|
|
|
|
|
|
||
Total first-year premium collections on insurance products
|
245.5
|
|
|
278.0
|
|
||
Total renewal premium collections on insurance products
|
338.8
|
|
|
338.2
|
|
||
Total collections on insurance products
|
$
|
584.3
|
|
|
$
|
616.2
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premiums collected by product:
|
|
|
|
||||
Health:
|
|
|
|
||||
Medicare supplement (first-year)
|
$
|
.3
|
|
|
$
|
.6
|
|
Medicare supplement (renewal)
|
27.8
|
|
|
34.7
|
|
||
Subtotal - Medicare supplement
|
28.1
|
|
|
35.3
|
|
||
Supplemental health (first-year)
|
14.1
|
|
|
13.2
|
|
||
Supplemental health (renewal)
|
98.8
|
|
|
93.7
|
|
||
Subtotal – supplemental health
|
112.9
|
|
|
106.9
|
|
||
Other health (all renewal)
|
.7
|
|
|
1.0
|
|
||
Total health
|
141.7
|
|
|
143.2
|
|
||
Life insurance:
|
|
|
|
||||
First-year
|
.2
|
|
|
.4
|
|
||
Renewal
|
3.8
|
|
|
3.9
|
|
||
Total life insurance
|
4.0
|
|
|
4.3
|
|
||
Collections on insurance products:
|
|
|
|
||||
Total first-year premium collections on insurance products
|
14.6
|
|
|
14.2
|
|
||
Total renewal premium collections on insurance products
|
131.1
|
|
|
133.3
|
|
||
Total collections on insurance products
|
$
|
145.7
|
|
|
$
|
147.5
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premiums collected by product:
|
|
|
|
||||
Life insurance:
|
|
|
|
||||
First-year
|
$
|
10.4
|
|
|
$
|
8.7
|
|
Renewal
|
42.2
|
|
|
40.7
|
|
||
Total life insurance
|
52.6
|
|
|
49.4
|
|
||
Health (all renewal):
|
|
|
|
||||
Medicare supplement
|
1.2
|
|
|
1.3
|
|
||
Other health
|
.1
|
|
|
.2
|
|
||
Total health
|
1.3
|
|
|
1.5
|
|
||
Collections on insurance products:
|
|
|
|
||||
Total first-year premium collections on insurance products
|
10.4
|
|
|
8.7
|
|
||
Total renewal premium collections on insurance products
|
43.5
|
|
|
42.2
|
|
||
Total collections on insurance products
|
$
|
53.9
|
|
|
$
|
50.9
|
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Premiums collected by product:
|
|
|
|
||||
Annuities:
|
|
|
|
||||
Fixed index (first-year)
|
$
|
—
|
|
|
$
|
2.7
|
|
Fixed index (renewal)
|
.7
|
|
|
.9
|
|
||
Subtotal - fixed index annuities
|
.7
|
|
|
3.6
|
|
||
Other fixed rate (first-year)
|
—
|
|
|
.4
|
|
||
Other fixed rate (renewal)
|
.2
|
|
|
.2
|
|
||
Subtotal - other fixed rate annuities
|
.2
|
|
|
.6
|
|
||
Total annuities
|
.9
|
|
|
4.2
|
|
||
Health:
|
|
|
|
||||
Long-term care (all renewal)
|
6.7
|
|
|
7.4
|
|
||
Other health (all renewal)
|
.2
|
|
|
.2
|
|
||
Total health
|
6.9
|
|
|
7.6
|
|
||
Life insurance:
|
|
|
|
||||
First-year
|
.6
|
|
|
.4
|
|
||
Renewal
|
44.7
|
|
|
46.0
|
|
||
Total life insurance
|
45.3
|
|
|
46.4
|
|
||
Collections on insurance products:
|
|
|
|
||||
Total first-year premium collections on insurance products
|
.6
|
|
|
3.5
|
|
||
Total renewal premium collections on insurance products
|
52.5
|
|
|
54.7
|
|
||
Total collections on insurance products
|
$
|
53.1
|
|
|
$
|
58.2
|
|
|
March 31,
|
|
December 31,
|
||||
|
2012
|
|
2011
|
||||
Total capital:
|
|
|
|
||||
Corporate notes payable
|
$
|
799.3
|
|
|
$
|
857.9
|
|
Shareholders’ equity:
|
|
|
|
|
|||
Common stock
|
2.4
|
|
|
2.4
|
|
||
Additional paid-in capital
|
4,345.6
|
|
|
4,361.9
|
|
||
Accumulated other comprehensive income
|
808.0
|
|
|
781.6
|
|
||
Accumulated deficit
|
(473.0
|
)
|
|
(532.1
|
)
|
||
Total shareholders’ equity
|
4,683.0
|
|
|
4,613.8
|
|
||
Total capital
|
$
|
5,482.3
|
|
|
$
|
5,471.7
|
|
|
March 31,
|
|
December 31,
|
||||
|
2012
|
|
2011
|
||||
Book value per common share
|
$
|
19.58
|
|
|
$
|
19.12
|
|
Book value per common share, excluding accumulated other comprehensive income (a)
|
16.20
|
|
|
15.88
|
|
||
Ratio of earnings to fixed charges
|
1.92X
|
|
|
1.75X
|
|
||
Debt to total capital ratios:
|
|
|
|
|
|||
Corporate debt to total capital
|
14.6
|
%
|
|
15.7
|
%
|
||
Corporate debt to total capital, excluding accumulated other comprehensive income (a)
|
17.1
|
%
|
|
18.3
|
%
|
(a)
|
This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income. Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.
|
Amount
|
|
Maturity
|
|
Interest rate
|
||
borrowed
|
|
date
|
|
at March 31, 2012
|
||
$
|
100.0
|
|
|
October 2013
|
|
Variable rate – 0.572%
|
100.0
|
|
|
November 2013
|
|
Variable rate – 0.583%
|
|
67.0
|
|
|
February 2014
|
|
Fixed rate – 1.830%
|
|
50.0
|
|
|
August 2014
|
|
Variable rate – 0.633%
|
|
100.0
|
|
|
September 2015
|
|
Variable rate – 0.853%
|
|
150.0
|
|
|
October 2015
|
|
Variable rate – 0.592%
|
|
100.0
|
|
|
November 2015
|
|
Fixed rate – 4.890%
|
|
146.0
|
|
|
November 2015
|
|
Fixed rate – 5.300%
|
|
100.0
|
|
|
December 2015
|
|
Fixed rate – 4.710%
|
|
100.0
|
|
|
June 2016
|
|
Variable rate – 0.682%
|
|
75.0
|
|
|
June 2016
|
|
Variable rate – 0.630%
|
|
75.0
|
|
|
August 2016
|
|
Variable rate – 0.701%
|
|
100.0
|
|
|
October 2016
|
|
Variable rate – 0.761%
|
|
50.0
|
|
|
November 2016
|
|
Variable rate – 0.750%
|
|
50.0
|
|
|
November 2016
|
|
Variable rate – 0.712%
|
|
100.0
|
|
|
June 2017
|
|
Variable rate – 0.763%
|
|
50.0
|
|
|
August 2017
|
|
Variable rate – 0.703%
|
|
100.0
|
|
|
October 2017
|
|
Variable rate – 1.002%
|
|
37.0
|
|
|
November 2017
|
|
Fixed rate – 3.750%
|
|
$
|
1,650.0
|
|
|
|
|
|
|
|
Earned surplus
|
|
|
||
Subsidiary of CDOC
|
|
(deficit)
|
|
Additional information
|
||
Subsidiaries of Conseco Life of Texas:
|
|
|
|
|
||
Bankers Life
|
|
$
|
249.3
|
|
|
(a)
|
Colonial Penn Life Insurance Company
|
|
(237.7
|
)
|
|
(b)
|
(a)
|
Bankers Life's ability to pay ordinary dividends is currently limited to its statutory net income in 2011 of $212.0 million.
|
(b)
|
The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.
|
(i)
|
a change in the definition of “Total Capitalization” (used to calculate compliance with the Debt to Total Capitalization Ratio covenant) to provide that any change to the Company's shareholders' equity resulting from the adoption by the Company of ASU 2010-26, related to the accounting for deferred acquisition costs, shall be disregarded for the purpose of such covenant to the extent the Company going forward quantifies the impact of ASU 2010-26 for each fiscal quarter or fiscal year and the cumulative impact since its adoption; and
|
(ii)
|
an increase in the cap on investments in “Capital Stock” (as defined in the amended credit agreement) from
1 percent
to
3 percent
.
|
Year ending March 31,
|
Principal
|
||
2013
|
33.8
|
|
|
2014
|
60.0
|
|
|
2015
|
77.5
|
|
|
2016
|
74.5
|
|
|
2017
|
293.0
|
|
|
Thereafter
|
275.0
|
|
|
|
$
|
813.8
|
|
•
|
incur or guarantee additional indebtedness or issue preferred stock;
|
•
|
pay dividends or make other distributions to shareholders;
|
•
|
purchase or redeem capital stock or subordinated indebtedness;
|
•
|
make certain investments;
|
•
|
create liens;
|
•
|
incur restrictions on the Company's ability and the ability of the Restricted Subsidiaries to pay dividends or make
|
•
|
other payments to the Company;
|
•
|
sell assets, including capital stock of the Company's subsidiaries;
|
•
|
consolidate or merge with or into other companies or transfer all or substantially all of the Company's assets; and
|
•
|
engage in transactions with affiliates.
|
|
Amortized
cost
|
|
Gross
unrealized
gains
|
|
Gross
unrealized
losses
|
|
Estimated
fair
value
|
||||||||
Investment grade (a):
|
|
|
|
|
|
|
|
||||||||
Corporate securities
|
$
|
13,364.8
|
|
|
$
|
1,383.9
|
|
|
$
|
(45.3
|
)
|
|
$
|
14,703.4
|
|
United States Treasury securities and obligations of United States government corporations and agencies
|
286.7
|
|
|
5.5
|
|
|
(3.1
|
)
|
|
289.1
|
|
||||
States and political subdivisions
|
1,788.2
|
|
|
203.9
|
|
|
(8.2
|
)
|
|
1,983.9
|
|
||||
Debt securities issued by foreign governments
|
.8
|
|
|
—
|
|
|
—
|
|
|
.8
|
|
||||
Asset-backed securities
|
1,190.7
|
|
|
45.2
|
|
|
(19.0
|
)
|
|
1,216.9
|
|
||||
Collateralized debt obligations
|
327.8
|
|
|
2.1
|
|
|
(2.4
|
)
|
|
327.5
|
|
||||
Commercial mortgage-backed securities
|
1,399.7
|
|
|
103.5
|
|
|
(3.9
|
)
|
|
1,499.3
|
|
||||
Mortgage pass-through securities
|
28.5
|
|
|
1.6
|
|
|
—
|
|
|
30.1
|
|
||||
Collateralized mortgage obligations
|
1,321.6
|
|
|
74.0
|
|
|
(2.0
|
)
|
|
1,393.6
|
|
||||
Total investment grade fixed maturities, available for sale
|
19,708.8
|
|
|
1,819.7
|
|
|
(83.9
|
)
|
|
21,444.6
|
|
||||
Below-investment grade (a):
|
|
|
|
|
|
|
|
|
|
|
|
||||
Corporate securities
|
1,209.3
|
|
|
41.4
|
|
|
(31.8
|
)
|
|
1,218.9
|
|
||||
Asset-backed securities
|
192.3
|
|
|
3.7
|
|
|
(5.9
|
)
|
|
190.1
|
|
||||
Collateralized debt obligations
|
5.3
|
|
|
.1
|
|
|
(.5
|
)
|
|
4.9
|
|
||||
Collateralized mortgage obligations
|
905.5
|
|
|
20.2
|
|
|
(6.5
|
)
|
|
919.2
|
|
||||
Total below-investment grade fixed maturities, available for sale
|
2,312.4
|
|
|
65.4
|
|
|
(44.7
|
)
|
|
2,333.1
|
|
||||
Total fixed maturities, available for sale
|
$
|
22,021.2
|
|
|
$
|
1,885.1
|
|
|
$
|
(128.6
|
)
|
|
$
|
23,777.7
|
|
Equity securities
|
$
|
172.7
|
|
|
$
|
4.1
|
|
|
$
|
(.3
|
)
|
|
$
|
176.5
|
|
(a)
|
Investment ratings – Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody’s, S&P or Fitch), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of “1” or “2” include fixed maturities generally rated investment grade (rated “Baa3” or higher by Moody’s or rated “BBB-” or higher by S&P and Fitch). NAIC designations of “3” through “6” are referred to as below-investment grade (which generally are rated “Ba1” or lower by Moody’s or rated “BB+” or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.
|
NAIC Designation
|
|
NRSRO Equivalent Rating
|
|
|
|
1
|
|
AAA/AA/A
|
2
|
|
BBB
|
3
|
|
BB
|
4
|
|
B
|
5
|
|
CCC and lower
|
6
|
|
In or near default
|
|
|
|
|
|
|
Percentage
|
|||||
|
|
|
|
Estimated
|
|
of total
|
|||||
NAIC
|
|
Amortized
|
|
fair
|
|
estimated
|
|||||
designation
|
|
cost
|
|
value
|
|
fair value
|
|||||
|
|
|
|
|
|
|
|||||
1
|
|
$
|
10,639.4
|
|
|
$
|
11,545.4
|
|
|
48.6
|
%
|
2
|
|
10,015.9
|
|
|
10,855.8
|
|
|
45.6
|
|
||
3
|
|
1,028.2
|
|
|
1,038.8
|
|
|
4.4
|
|
||
4
|
|
294.4
|
|
|
298.5
|
|
|
1.2
|
|
||
5
|
|
42.9
|
|
|
38.7
|
|
|
.2
|
|
||
6
|
|
.4
|
|
|
.5
|
|
|
—
|
|
||
|
|
$
|
22,021.2
|
|
|
$
|
23,777.7
|
|
|
100.0
|
%
|
|
Carrying value
|
|
Percent of
fixed maturities
|
|
Gross
unrealized
losses
|
|
Percent of
gross
unrealized
losses
|
||||||
Energy/pipelines
|
$
|
2,359.2
|
|
|
9.9
|
%
|
|
$
|
7.5
|
|
|
5.8
|
%
|
Collateralized mortgage obligations
|
2,312.8
|
|
|
9.7
|
|
|
8.5
|
|
|
6.6
|
|
||
Utilities
|
2,068.0
|
|
|
8.7
|
|
|
4.0
|
|
|
3.1
|
|
||
States and political subdivisions
|
1,983.9
|
|
|
8.4
|
|
|
8.2
|
|
|
6.4
|
|
||
Commercial mortgage-backed securities
|
1,499.3
|
|
|
6.3
|
|
|
3.9
|
|
|
3.0
|
|
||
Asset-backed securities
|
1,407.0
|
|
|
5.9
|
|
|
24.9
|
|
|
19.4
|
|
||
Insurance
|
1,391.3
|
|
|
5.9
|
|
|
5.4
|
|
|
4.2
|
|
||
Healthcare/pharmaceuticals
|
1,206.4
|
|
|
5.1
|
|
|
2.1
|
|
|
1.7
|
|
||
Food/beverage
|
1,121.6
|
|
|
4.7
|
|
|
2.5
|
|
|
1.9
|
|
||
Real estate/REITs
|
896.4
|
|
|
3.8
|
|
|
1.1
|
|
|
.8
|
|
||
Cable/media
|
895.4
|
|
|
3.8
|
|
|
6.9
|
|
|
5.4
|
|
||
Banks
|
772.9
|
|
|
3.3
|
|
|
14.9
|
|
|
11.6
|
|
||
Capital goods
|
699.1
|
|
|
3.0
|
|
|
1.7
|
|
|
1.3
|
|
||
Transportation
|
526.9
|
|
|
2.2
|
|
|
.2
|
|
|
.2
|
|
||
Telecom
|
504.7
|
|
|
2.1
|
|
|
11.9
|
|
|
9.3
|
|
||
Aerospace/defense
|
432.9
|
|
|
1.8
|
|
|
—
|
|
|
—
|
|
||
Chemicals
|
387.8
|
|
|
1.6
|
|
|
—
|
|
|
—
|
|
||
Building materials
|
380.1
|
|
|
1.6
|
|
|
11.6
|
|
|
9.0
|
|
||
Metals and mining
|
350.9
|
|
|
1.5
|
|
|
.3
|
|
|
.2
|
|
||
Paper
|
342.2
|
|
|
1.4
|
|
|
2.1
|
|
|
1.7
|
|
||
Collateralized debt obligations
|
332.4
|
|
|
1.4
|
|
|
2.9
|
|
|
2.3
|
|
||
Consumer products
|
305.0
|
|
|
1.3
|
|
|
1.5
|
|
|
1.1
|
|
||
U.S. Treasury and Obligations
|
289.1
|
|
|
1.2
|
|
|
3.1
|
|
|
2.4
|
|
||
Brokerage
|
268.0
|
|
|
1.1
|
|
|
2.2
|
|
|
1.7
|
|
||
Technology
|
246.5
|
|
|
1.0
|
|
|
.5
|
|
|
.4
|
|
||
Other
|
797.9
|
|
|
3.3
|
|
|
.7
|
|
|
.5
|
|
||
Total fixed maturities, available for sale
|
$
|
23,777.7
|
|
|
100.0
|
%
|
|
$
|
128.6
|
|
|
100.0
|
%
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Fixed maturity securities, available for sale:
|
|
|
|
||||
Realized gains on sale
|
$
|
28.7
|
|
|
$
|
41.2
|
|
Realized losses on sale
|
(2.3
|
)
|
|
(24.6
|
)
|
||
Impairments:
|
|
|
|
||||
Total other-than-temporary impairment losses
|
(.4
|
)
|
|
(6.5
|
)
|
||
Other-than-temporary impairment losses recognized in accumulated other comprehensive income (loss)
|
—
|
|
|
—
|
|
||
Net impairment losses recognized
|
(.4
|
)
|
|
(6.5
|
)
|
||
Net realized investment gains (losses) from fixed maturities
|
26.0
|
|
|
10.1
|
|
||
Commercial mortgage loans
|
.5
|
|
|
(.4
|
)
|
||
Impairments of mortgage loans and other investments
|
(7.5
|
)
|
|
(6.8
|
)
|
||
Other
|
3.9
|
|
|
2.2
|
|
||
Net realized investment gains
|
$
|
22.9
|
|
|
$
|
5.1
|
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
46.1
|
|
|
$
|
46.1
|
|
Due after one year through five years
|
144.4
|
|
|
142.1
|
|
||
Due after five years through ten years
|
515.0
|
|
|
499.3
|
|
||
Due after ten years
|
1,301.9
|
|
|
1,231.5
|
|
||
Subtotal
|
2,007.4
|
|
|
1,919.0
|
|
||
Structured securities
|
1,266.3
|
|
|
1,226.1
|
|
||
Total
|
$
|
3,273.7
|
|
|
$
|
3,145.1
|
|
|
Number
of issuers
|
|
Cost
basis
|
|
Unrealized
loss
|
|
Estimated
fair value
|
||||||
Greater than or equal to 6 months and less than 12 months
|
3
|
|
$
|
15.2
|
|
|
(3.6
|
)
|
|
$
|
11.6
|
|
|
|
3
|
|
$
|
15.2
|
|
|
$
|
(3.6
|
)
|
|
$
|
11.6
|
|
|
|
Investment grade
|
|
Below investment grade
|
|
|
||||||||||||||
|
|
AAA/AA/A
|
|
BBB
|
|
BB
|
|
B+ and
below
|
|
Total gross
unrealized
losses |
||||||||||
Asset-backed securities
|
|
$
|
8.4
|
|
|
$
|
10.6
|
|
|
$
|
5.3
|
|
|
$
|
.6
|
|
|
$
|
24.9
|
|
Banks
|
|
2.1
|
|
|
10.2
|
|
|
2.6
|
|
|
—
|
|
|
14.9
|
|
|||||
Telecom
|
|
—
|
|
|
9.2
|
|
|
.6
|
|
|
2.1
|
|
|
11.9
|
|
|||||
Building materials
|
|
.1
|
|
|
3.7
|
|
|
7.8
|
|
|
—
|
|
|
11.6
|
|
|||||
Collateralized mortgage obligations
|
|
1.8
|
|
|
.2
|
|
|
.2
|
|
|
6.3
|
|
|
8.5
|
|
|||||
States and political subdivisions
|
|
2.5
|
|
|
5.7
|
|
|
—
|
|
|
—
|
|
|
8.2
|
|
|||||
Energy/pipelines
|
|
.1
|
|
|
1.6
|
|
|
5.7
|
|
|
.1
|
|
|
7.5
|
|
|||||
Cable/media
|
|
—
|
|
|
.1
|
|
|
4.1
|
|
|
2.7
|
|
|
6.9
|
|
|||||
Insurance
|
|
.4
|
|
|
4.0
|
|
|
1.0
|
|
|
—
|
|
|
5.4
|
|
|||||
Utilities
|
|
.2
|
|
|
3.8
|
|
|
—
|
|
|
—
|
|
|
4.0
|
|
|||||
Commercial mortgage-backed securities
|
|
3.5
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
3.9
|
|
|||||
U.S. Treasury and Obligations
|
|
3.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.1
|
|
|||||
Collateralized debt obligations
|
|
2.4
|
|
|
—
|
|
|
—
|
|
|
.5
|
|
|
2.9
|
|
|||||
Food/beverage
|
|
—
|
|
|
2.4
|
|
|
—
|
|
|
.1
|
|
|
2.5
|
|
|||||
Healthcare/pharmaceuticals
|
|
.1
|
|
|
1.6
|
|
|
.1
|
|
|
.4
|
|
|
2.2
|
|
|||||
Brokerage
|
|
2.0
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
2.1
|
|
|||||
Paper
|
|
—
|
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
2.1
|
|
|||||
Capital goods
|
|
—
|
|
|
1.7
|
|
|
—
|
|
|
—
|
|
|
1.7
|
|
|||||
Consumer products
|
|
—
|
|
|
.2
|
|
|
1.3
|
|
|
—
|
|
|
1.5
|
|
|||||
Real estate/REITs
|
|
—
|
|
|
.5
|
|
|
.6
|
|
|
—
|
|
|
1.1
|
|
|||||
Technology
|
|
—
|
|
|
.4
|
|
|
—
|
|
|
.1
|
|
|
.5
|
|
|||||
Metals and mining
|
|
—
|
|
|
.1
|
|
|
.2
|
|
|
—
|
|
|
.3
|
|
|||||
Gaming
|
|
—
|
|
|
—
|
|
|
—
|
|
|
.2
|
|
|
.2
|
|
|||||
Transportation
|
|
—
|
|
|
.2
|
|
|
—
|
|
|
—
|
|
|
.2
|
|
|||||
Autos
|
|
—
|
|
|
.1
|
|
|
—
|
|
|
—
|
|
|
.1
|
|
|||||
Other
|
|
—
|
|
|
.4
|
|
|
—
|
|
|
—
|
|
|
.4
|
|
|||||
Total fixed maturities, available for sale
|
|
$
|
26.7
|
|
|
$
|
57.2
|
|
|
$
|
31.6
|
|
|
$
|
13.1
|
|
|
$
|
128.6
|
|
|
|
Less than 12 months
|
|
12 months or greater
|
|
Total
|
||||||||||||||||||
Description of securities
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
|
Fair
value
|
|
Unrealized
losses
|
||||||||||||
United States Treasury securities and obligations of United States government corporations and agencies
|
|
$
|
195.3
|
|
|
$
|
(3.1
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
195.3
|
|
|
$
|
(3.1
|
)
|
States and political subdivisions
|
|
4.1
|
|
|
(.3
|
)
|
|
126.4
|
|
|
(7.9
|
)
|
|
130.5
|
|
|
(8.2
|
)
|
||||||
Corporate securities
|
|
1,204.7
|
|
|
(38.9
|
)
|
|
388.5
|
|
|
(38.2
|
)
|
|
1,593.2
|
|
|
(77.1
|
)
|
||||||
Asset-backed securities
|
|
287.7
|
|
|
(6.7
|
)
|
|
211.8
|
|
|
(18.2
|
)
|
|
499.5
|
|
|
(24.9
|
)
|
||||||
Collateralized debt obligations
|
|
198.5
|
|
|
(2.7
|
)
|
|
11.0
|
|
|
(.2
|
)
|
|
209.5
|
|
|
(2.9
|
)
|
||||||
Commercial mortgage-backed securities
|
|
89.6
|
|
|
(2.0
|
)
|
|
29.2
|
|
|
(1.9
|
)
|
|
118.8
|
|
|
(3.9
|
)
|
||||||
Mortgage pass-through securities
|
|
.5
|
|
|
—
|
|
|
2.2
|
|
|
—
|
|
|
2.7
|
|
|
—
|
|
||||||
Collateralized mortgage obligations
|
|
331.9
|
|
|
(6.0
|
)
|
|
63.7
|
|
|
(2.5
|
)
|
|
395.6
|
|
|
(8.5
|
)
|
||||||
Total fixed maturities, available for sale
|
|
$
|
2,312.3
|
|
|
$
|
(59.7
|
)
|
|
$
|
832.8
|
|
|
$
|
(68.9
|
)
|
|
$
|
3,145.1
|
|
|
$
|
(128.6
|
)
|
Equity securities
|
|
$
|
3.5
|
|
|
$
|
(.3
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3.5
|
|
|
$
|
(.3
|
)
|
|
Par
value
|
|
Amortized
cost
|
|
Estimated
fair value
|
||||||
Below 4 percent
|
$
|
598.9
|
|
|
$
|
552.8
|
|
|
$
|
550.7
|
|
4 percent – 5 percent
|
740.0
|
|
|
725.4
|
|
|
771.2
|
|
|||
5 percent – 6 percent
|
2,856.7
|
|
|
2,737.4
|
|
|
2,859.5
|
|
|||
6 percent – 7 percent
|
1,032.3
|
|
|
991.0
|
|
|
1,024.4
|
|
|||
7 percent – 8 percent
|
176.4
|
|
|
182.2
|
|
|
189.0
|
|
|||
8 percent and above
|
177.4
|
|
|
182.6
|
|
|
186.8
|
|
|||
Total structured securities
|
$
|
5,581.7
|
|
|
$
|
5,371.4
|
|
|
$
|
5,581.6
|
|
|
|
|
Estimated fair value
|
|||||||
Type
|
Amortized
cost
|
|
Amount
|
|
Percent
of fixed
maturities
|
|||||
Pass-throughs, sequential and equivalent securities
|
$
|
1,463.3
|
|
|
$
|
1,517.4
|
|
|
6.4
|
%
|
Planned amortization classes, target amortization classes and accretion-directed bonds
|
770.1
|
|
|
802.8
|
|
|
3.4
|
|
||
Commercial mortgage-backed securities
|
1,399.7
|
|
|
1,499.3
|
|
|
6.3
|
|
||
Asset-backed securities
|
1,383.0
|
|
|
1,407.0
|
|
|
5.9
|
|
||
Collateralized debt obligations
|
333.1
|
|
|
332.4
|
|
|
1.4
|
|
||
Other
|
22.2
|
|
|
22.7
|
|
|
.1
|
|
||
Total structured securities
|
$
|
5,371.4
|
|
|
$
|
5,581.6
|
|
|
23.5
|
%
|
Loan-to-value ratio (a)
|
Carrying value
|
|
Estimated fair
value
|
||||
Less than 60%
|
$
|
720.2
|
|
|
$
|
800.8
|
|
60% to 70%
|
347.9
|
|
|
368.7
|
|
||
70% to 80%
|
178.3
|
|
|
184.6
|
|
||
80% to 90%
|
189.4
|
|
|
195.3
|
|
||
Greater than 90%
|
110.9
|
|
|
113.0
|
|
||
Total
|
$
|
1,546.7
|
|
|
$
|
1,662.4
|
|
(a)
|
Loan-to-value ratios are calculated as the ratio of: (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying commercial property, which is updated on a periodic basis as part of our ongoing credit assessment of the loan portfolio.
|
|
Three months ended
|
||||||
|
March 31,
|
||||||
|
2012
|
|
2011
|
||||
Revenues:
|
|
|
|
||||
Net investment income – policyholder and reinsurer accounts and other special-purpose portfolios
|
$
|
6.1
|
|
|
$
|
4.4
|
|
Fee revenue and other income
|
.2
|
|
|
.2
|
|
||
Total revenues
|
6.3
|
|
|
4.6
|
|
||
Expenses:
|
|
|
|
||||
Interest expense
|
4.0
|
|
|
2.5
|
|
||
Other operating expenses
|
.1
|
|
|
.1
|
|
||
Total expenses
|
4.1
|
|
|
2.6
|
|
||
Income before net realized investment losses and income taxes
|
2.2
|
|
|
2.0
|
|
||
Net realized investment gains (losses)
|
(.5
|
)
|
|
(1.4
|
)
|
||
Income (loss) before income taxes
|
$
|
1.7
|
|
|
$
|
.6
|
|
|
Carrying value
|
|
Percent
of fixed
maturities
|
|
Gross
unrealized
losses
|
|
Percent of
gross
unrealized
losses
|
||||||
Healthcare/pharmaceuticals
|
$
|
68.1
|
|
|
12.1
|
%
|
|
$
|
1.0
|
|
|
23.8
|
%
|
Cable/media
|
67.9
|
|
|
12.0
|
|
|
.3
|
|
|
8.0
|
|
||
Technology
|
49.9
|
|
|
8.8
|
|
|
.2
|
|
|
4.3
|
|
||
Autos
|
42.0
|
|
|
7.5
|
|
|
.1
|
|
|
1.3
|
|
||
Food/beverage
|
37.4
|
|
|
6.6
|
|
|
.1
|
|
|
2.2
|
|
||
Gaming
|
29.6
|
|
|
5.3
|
|
|
.1
|
|
|
2.2
|
|
||
Brokerage
|
23.2
|
|
|
4.1
|
|
|
.1
|
|
|
3.7
|
|
||
Retail
|
19.8
|
|
|
3.5
|
|
|
—
|
|
|
.6
|
|
||
Consumer products
|
18.9
|
|
|
3.4
|
|
|
.8
|
|
|
19.5
|
|
||
Capital goods
|
18.2
|
|
|
3.2
|
|
|
—
|
|
|
.5
|
|
||
Entertainment/hotels
|
17.9
|
|
|
3.2
|
|
|
.6
|
|
|
14.0
|
|
||
Building materials
|
16.8
|
|
|
3.0
|
|
|
—
|
|
|
.7
|
|
||
Insurance
|
16.5
|
|
|
2.9
|
|
|
—
|
|
|
.7
|
|
||
Telecom
|
16.2
|
|
|
2.9
|
|
|
.1
|
|
|
2.1
|
|
||
Chemicals
|
14.1
|
|
|
2.5
|
|
|
—
|
|
|
1.2
|
|
||
Aerospace/defense
|
12.8
|
|
|
2.3
|
|
|
—
|
|
|
.3
|
|
||
Real estate/REITs
|
9.9
|
|
|
1.8
|
|
|
.1
|
|
|
1.6
|
|
||
Transportation
|
9.8
|
|
|
1.7
|
|
|
.1
|
|
|
2.3
|
|
||
Energy/pipelines
|
9.8
|
|
|
1.7
|
|
|
.1
|
|
|
1.8
|
|
||
Paper
|
9.8
|
|
|
1.7
|
|
|
—
|
|
|
.4
|
|
||
Utilities
|
6.5
|
|
|
1.1
|
|
|
—
|
|
|
.6
|
|
||
Metals and mining
|
5.4
|
|
|
.9
|
|
|
—
|
|
|
.1
|
|
||
Other
|
44.2
|
|
|
7.8
|
|
|
.3
|
|
|
8.1
|
|
||
Total
|
$
|
564.7
|
|
|
100.0
|
%
|
|
$
|
4.0
|
|
|
100.0
|
%
|
|
Amortized
cost
|
|
Estimated
fair
value
|
||||
|
(Dollars in millions)
|
||||||
Due in one year or less
|
$
|
.3
|
|
|
$
|
.3
|
|
Due after one year through five years
|
179.9
|
|
|
176.6
|
|
||
Due after five years through ten years
|
109.9
|
|
|
109.2
|
|
||
Total
|
$
|
290.1
|
|
|
$
|
286.1
|
|
Period
|
|
Total number of shares (or units)
|
|
Average price paid per share
(or unit)
|
|
Total number of shares (or units) purchased as part of publicly announced plans or programs
|
|
Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(a)
|
||||||
|
|
|
|
|
|
|
|
(dollars in millions)
|
||||||
January 1 through January 31
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
30.2
|
|
February 1 through February 29
|
|
229,292
|
|
|
7.52
|
|
|
229,292
|
|
|
128.5
|
|
||
March 1 through March 31
|
|
2,349,527
|
|
|
7.77
|
|
|
2,207,638
|
|
|
111.3
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Total
|
|
2,578,819
|
|
|
7.75
|
|
|
2,436,930
|
|
|
111.3
|
|
(a)
|
In May 2011, the Company announced a common share repurchase program of up to $100.0 million. In February 2012, the Company announced that its board of directors had approved an additional $100.0 million to repurchase the Company's outstanding common stock.
|
10.1
|
Amendment to Employment Agreement dated as of April 30, 2012 between CNO Services, LLC and Susan L. Menzel.
|
|
|
10.2
|
Amendment to Employment Agreement dated as of April 30, 2012 between CNO Services, LLC and Matthew J. Zimpfer.
|
|
|
12.1
|
Computation of Ratio of Earnings to Fixed Charges.
|
|
|
31.1
|
Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
31.2
|
Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
32.1
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
32.2
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
101.INS
|
XBRL Instance Document.
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document.
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
By:
|
/s/ Frederick J. Crawford
|
|
|
Frederick J. Crawford
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
(authorized officer and principal financial officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Customers Found
Suppliers
Supplier name | Ticker |
---|---|
Johnson & Johnson | JNJ |
Pfizer Inc. | PFE |
Merck & Co., Inc. | MRK |
Abbott Laboratories | ABT |
Bristol-Myers Squibb Company | BMY |
AbbVie Inc. | ABBV |
Amgen Inc. | AMGN |
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|